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Abstract
Mitochondrial dysfunction has been observed in skeletal muscle of people with diabetes and insulin-resistant individuals.
Furthermore, inherited mutations in mitochondrial DNA can cause a rare form of diabetes. However, it is unclear whether
mitochondrial dysfunction is a primary cause of the common form of diabetes. To date, common genetic variants robustly
associated with type 2 diabetes (T2D) are not known to affect mitochondrial function. One possibility is that multiple
mitochondrial genes contain modest genetic effects that collectively influence T2D risk. To test this hypothesis we
developed a method named Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA; http://www.
broadinstitute.org/mpg/magenta). MAGENTA, in analogy to Gene Set Enrichment Analysis, tests whether sets of functionally
related genes are enriched for associations with a polygenic disease or trait. MAGENTA was specifically designed to exploit
the statistical power of large genome-wide association (GWA) study meta-analyses whose individual genotypes are not
available. This is achieved by combining variant association p-values into gene scores and then correcting for confounders,
such as gene size, variant number, and linkage disequilibrium properties. Using simulations, we determined the range of
parameters for which MAGENTA can detect associations likely missed by single-marker analysis. We verified MAGENTA’s
performance on empirical data by identifying known relevant pathways in lipid and lipoprotein GWA meta-analyses. We
then tested our mitochondrial hypothesis by applying MAGENTA to three gene sets: nuclear regulators of mitochondrial
genes, oxidative phosphorylation genes, and ,1,000 nuclear-encoded mitochondrial genes. The analysis was performed
using the most recent T2D GWA meta-analysis of 47,117 people and meta-analyses of seven diabetes-related glycemic traits
(up to 46,186 non-diabetic individuals). This well-powered analysis found no significant enrichment of associations to T2D or
any of the glycemic traits in any of the gene sets tested. These results suggest that common variants affecting nuclear-
encoded mitochondrial genes have at most a small genetic contribution to T2D susceptibility.
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Introduction
Mitochondrial dysfunction has been implicated in both rare and
common forms of type 2 diabetes (T2D) [1–4]. Individuals with
T2D contain less mitochondria in their skeletal muscle [5,6], and
impaired mitochondrial function has been associated with T2D
and insulin resistance, an intermediate phenotype and risk factor
of diabetes [7]. In particular, oxidative phosphorylation (OX-
PHOS) activity in mitochondria, central for energy production in
the cell, is reduced in certain populations of diabetic and insulin-
resistant individuals [5,8]. Furthermore, we found that the
expression of OXPHOS genes is coordinately downregulated in
diabetic versus healthy muscle [9,10]. It has been proposed that
decreased OXPHOS activity may contribute to T2D development
by causing fatty acid accumulation in muscle cells, which in turn
may inhibit insulin-stimulated glucose uptake [1,2,7,8,11], or by
indirectly reducing glucose-stimulated insulin secretion from
pancreatic ß-cells due to a decrease in ATP production [1].
However, it is still not clear whether the molecular and physiologic
associations of mitochondria with diabetes are a cause or effect of
the common form of T2D [1,2,12].
One way to test whether mitochondrial genes play a causal role
in the pathogenesis of T2D is to search for inherited DNA variants
in mitochondrial genes that influence T2D risk. Proof of concept
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cause Maternally Inherited Diabetes with Deafness (OMIM
#520000). This raises the question of whether inherited variants
affecting mitochondrial biology play a more general causal role in
the common form of T2D. Candidate gene studies of mitochon-
dria-related genes have yet to conclusively demonstrate (at
genome-wide significance) that common variants in nuclear-
encoded mitochondrial genes or transcriptional regulators of
mitochondrial genes associate with T2D risk [13–15]. Also, we
published a systematic scan for associations of common single-
nucleotide polymorphisms (SNPs) in mtDNA (that encodes 13
genes) that failed to identify significant associations with T2D [16].
Recently, several genome-wide association (GWA) studies of
,2,000 to 5,000 individuals [17–19], and a meta-analysis of
10,128 individuals [20], all of European descent, have identified
,18 common nuclear DNA variants robustly associated with T2D
that collectively explain ,6% of the genetic contribution to T2D
risk. While these associations suggest genes involved in various
biological processes, such as WNT signaling, NOTCH signaling
and the cell cycle, none have implicated mitochondrial processes.
The only gene with a mitochondrial isoform near a validated T2D
SNP is the insulin-degrading enzyme, IDE (Entrez ID 3416), but it
exerts its insulin degrading activity primarily in the cytoplasm [21].
Given the large number of nuclear-encoded mitochondrial
genes (,1,000 known based on the mitochondrial protein
compendium MitoCarta [22]) and the largely unexplained genetic
basis of T2D, it is possible that many (tens or hundreds of)
common variants in or near mitochondrial genes are associated
with T2D. While each gene might have a modest effect too small
to be detected on its own, together they could have a more
substantial collective impact. It is also possible that several nuclear
regulators of mitochondrial genes could harbor common variants
of modest effects on T2D risk.
These hypotheses could be tested using a Gene Set Enrichment
Analysis (GSEA) approach applied to genetic variant association
data [23]. We originally described GSEA to test whether
predefined biological processes or gene sets are enriched for genes
with coordinate modest expression differences between two
samples, differences that are hard to detect when inspecting each
gene separately [9,24]. In fact, GSEA was first used to show that
OXPHOS genes are collectively downregulated in human muscle
in diabetic compared to non-diabetic individuals [9].
In the context of genetic association data, GSEA has been
suggested to be a promising approach to identify sets of
functionally related genes, such as biological pathways, enriched
for associations of modest effects (hard to detect with single-marker
analysis) on a polygenic disease or trait [23]. Several groups have
begun to apply different variations of GSEA to GWA studies to
study disorders such as Parkinson’s disease [23], dyslipidemia [25],
T2D [26–28], Crohn’s disease [25,29,30], and multiple sclerosis
[31]. While the principal concept is similar in these studies,
alternative implementations differ substantially, for example in
how genes are scored or enrichment is evaluated. In addition,
researchers have only begun to evaluate the ranges of parameters
(e.g. effect size or fraction of causal genes) under which gene-set
approaches have power to identify associations not found by
single-variant analysis [32,33].
To maximize power, it is critical to make use of meta-analyses of
multiple independent GWA studies whose increasing sample size
(from thousands of people in single studies to tens of thousands in
meta-analyses) boosts the statistical power for detecting clustering
of modest associations. Yet, as opposed to traditional GWA
studies, information about individual genotypes is not available for
most meta-analyses, making it impossible to evaluate statistical
significance through standard phenotype permutation analysis.
While several GSEA variations have been recently applied to
meta-analyses, the extent to which they account for confounding
effects on gene association scores has not been tested.
Here we introduce a GSEA approach applied to genome-wide
variant association data, which we named ‘‘Meta-Analysis Gene-
set Enrichment of variaNT Associations’’ (MAGENTA). MA-
GENTA does not require genotype data, making it especially
relevant to GWA study meta-analyses. We tested and validated
MAGENTA using the Diabetes Genetics Initiative (DGI) GWA
study [17], and three GWA meta-analyses of cholesterol and lipid
blood levels [34]. Using simulations, we identified the conditions
under which our method has increased power to detect
associations for which there is low detection power with single
SNP analysis. Finally, to test whether mitochondrial dysfunction
may be causal to T2D, we applied MAGENTA to a set of known
nuclear regulators of mitochondrial genes [35], the OXPHOS
genes [9], and all known (,1,000) autosomal human mitochon-
drial genes [22], using the latest T2D meta-analysis of a total of
47,117 individuals (DIAGRAM+) [36], as well as meta-analyses
(up to 46,186 individuals) of seven glucose and insulin-related traits
relevant to T2D pathogenesis (MAGIC; [37,38], Soranzo N. et al.,
unpublished data).
Results
Meta-Analysis Gene-set Enrichment of variaNT Associations
(MAGENTA) evaluates pre-specified gene sets for enrichment of
modest associations with a complex disease or trait. MAGENTA
consists of four main steps: First, DNA variants, e.g. single-nucleotide
polymorphisms (SNPs), are mapped onto genes (Figure 1A). Second,
each gene is assigned a gene association score that is a function of its
regional SNP association p-values (Figure 1B). Third, confounding
effects on gene association scores are identified and corrected for,
without requiring genotype data (enabling use of meta-analyses or
other types of GWA studies where only variant association statistics
are available) (Figure 1C). Fourth, a Gene Set Enrichment Analysis
Author Summary
Mitochondria play a crucial role in metabolic homeostasis,
and alteration of mitochondrial function is a hallmark of
diabetes. While mitochondrial activity is reduced in people
with diabetes, it is unclear whether mitochondrial dys-
function is a cause or effect of type 2 diabetes. Genome-
wide association studies for type 2 diabetes have
explained <10% of the heritability of the disease, but
none of the loci are known to affect mitochondrial activity.
It is possible though that a mitochondrial contribution is
hidden in the remaining 90%. Hence, we tested the
hypothesis that multiple mitochondria-related genes
encoded in the nucleus, each having a weak effect (hard
to detect individually), can collectively influence type 2
diabetes. To address this, we developed a computational
method (MAGENTA) that allowed us to adequately analyze
large collective datasets of human genetic variation
obtained from collaborative studies of type 2 diabetes
and related glycemic traits. Despite the increased sensitiv-
ity of MAGENTA compared to single-DNA variant analysis,
we found no support for a causal relationship between
mitochondrial dysfunction and type 2 diabetes. These
results may help steer future efforts in understanding the
pathogenesis of the disease. MAGENTA is broadly appli-
cable to testing associations between other biological
pathways and common diseases or traits.
Mitochondrial Gene Set Analysis of Type 2 Diabetes
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relevant gene sets to determine whether any of the gene sets are
enriched for highly ranked gene association scores compared to
randomly sampled gene sets of identical size from the genome
(Figure 1D). These four steps are described below, and further
detailed in the Materials and Methods section.
From SNPs to genes: scoring genes based on SNP
association scores
To analyze genetic association data at the level of genes and
gene sets, we first needed to compute a gene score based on local
SNPs. We assigned to each gene g in the genome a set of SNPs that
lie within 110 kilobase (kb) upstream and 40 kb downstream of the
gene’s most extreme transcript boundaries, in attempt to capture
signals from potential causal variants affecting regulatory elements,
in addition to coding sequence (Figure 1A; see Materials and
Methods for boundary choice). Each gene g is then assigned a
score PBestSNP
g , defined in this instantiation as the most significant
p-value among the association p-values PSNP
i of all individual SNPs
i within the extended gene boundaries (Figure 1B). We used the
best SNP rather than an average value, as we expect only one or a
few associated variants per gene.
When PBestSNP
g was calculated for all 966 nuclear-encoded
mitochondrial genes using the T2D DIAGRAM+ GWA meta-
analysis, we found that their scores were on average less significant
than random (Figure S1). Observing that the mitochondrial genes
are smaller on average than all other genes in the genome (Table
S1), we next examined the effect of confounders on the most
Figure 1. Description of Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA) method. (A) Step 1: Map genetic
variants and their association scores onto genes. MAGENTA uses as input the association z-scores or p-values of DNA sequence variants across the
entire genome. In this work, we used association p-values of single-nucleotide polymorphisms, SNPs (circles) from a genome-wide association study
or meta-analysis, denoted as PSNP
i for SNP i. Gene boundaries (vertical dashed lines) are defined here as predetermined physical distances added
upstream and downstream to the most extreme transcript start and end sites of the gene (red arrow), respectively. Linkage-based distances can also
be used. Each gene is assigned a set of SNPs that fall in its gene region boundaries. Two genes are shown for simplicity. (B) Step 2: Score genes based
on their local SNP PSNP
i . Here the most significant PSNP
i of all SNPs i that lie within the extended gene boundaries is assigned to each gene g in the
genome (PBestSNP
g ). (C) Step 3: Correct for confounding effects on the gene score, PBestSNP
g in the absence of genotype data. In this study we used
step-wise multivariate linear regression analysis to regress out of PBestSNP
g the confounding effects of several physical and genetic properties of genes
(listed in Table 1); PGene0
g refers to the corrected gene p-value for gene g. In cases where two genes are assigned the same best SNP p-value, PGene0
g
tends to be more significant for small genes than for large genes. (D) Step 4: Calculate a gene set enrichment p-value for each biological pathway or
gene set of interest. We used a non-parametric statistical test to test whether PGene0
g for all genes in gene set gs are enriched for highly ranked gene
scores more than would be expected by chance, compared to randomly sampled gene sets of identical size from the genome. PGSEA
gs refers to the
nominal gene set enrichment p-value for gene set gs.
doi:10.1371/journal.pgen.1001058.g001
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g . Towards this goal, we
generated 1,000 null distributions of gene scores, through
phenotype permutations of the Diabetes Genetics Initiative
(DGI) GWA study, for which we have access to genotype data
(see Materials and Methods). In these randomized data sets no
genome-wide significant associations are expected. We observed
significant correlations of the scores for each gene across
permutations (mean Pearson’s correlation coefficient across all
genes for pairs of permutations: r=0.36). This suggested that
inherent properties of genes (not specific to the phenotype studied)
confound gene scores.
When we explicitly tested the potential confounding role of gene
size, previously suggested [23,25], we observed that large genes
tended to receive more significant scores than small genes in the
randomized data set (Figure S2).
Correcting for confounding effects on gene association
scores in the absence of genotype data
When genotype data are available, such as in individual GWA
studies, confounding effects on PBestSNP
g , e.g. gene size, can be
corrected for using phenotype permutation analysis that does not
require a priori knowledge of the confounders (described in
Materials and Methods). However, to exploit the power of large
GWA study meta-analyses, where permutation analysis cannot be
performed due to unavailability of genotype data, we needed an
alternative correction method. We chose a linear regression-based
approach that adjusts for the effects of multiple confounders on the
gene score. This required identifying a substantial amount of the
confounding effects on PBestSNP
g .
To find confounders on PBestSNP
g we systematically tested for
correlations between the unadjusted gene score, PBestSNP
g calculated
frompermuted DGIGWAstudy(seeMaterialsandMethods)and six
potential gene score confounders (listed in Table 1; correlations
reported for z-scores). We examined both physical properties of
genes - physical gene size and number of SNPs per kilobase for each
gene, and genetic properties that consider the dependency between
subsets of SNPs due to genetic linkage between proximal markers.
The genetic properties tested included estimated number of
independent SNPs per gene (SNPs in linkage equilibrium), number
of recombination hotspots spanning each gene, geneticdistance of the
gene, and linkage disequilibrium (LD) unit distance per gene,
normalized to the size of the gene and its extended boundaries (see
Materials and Methods). We found significant correlations for all six
properties tested (average values across 1,000 permuted data sets:
0.17,r,0.38; p,2e-70) (Table 1), suggesting that all variables may
have a confounding effect on PBestSNP
g . A similar trend was observed
using PBestSNP
g from the actual DGI GWA study (Table 1, column 2;
0.14,r,0.39, p,1e-74), and the T2D GWA meta-analysis, used
below to test the mitochondria-diabetes hypothesis (Table S2).
Having identified six potential gene score confounders, we used
step-wise multivariate linear regression to remove these confound-
ing effects from PBestSNP
g , to generate a corrected gene score,
PGene0
g (see Materials and Methods and Figure 1C). In this analysis
the confounders are removed sequentially, accounting for the
correlations between the various gene properties. Aside from the
genetic distance, all five remaining properties listed in Table 1
were significant under the step-wise linear regression model
(p,0.05) applied to PBestSNP
g in either about half or all of the 1,000
permuted DGI data sets (Table S3). As a result the first five
properties listed in Table 1 were used for subsequent analyses (see
Table S4 for model coefficients and p-values for the DGI study and
the DIAGRAM+ T2D meta-analysis).
The effectiveness of this approach was confirmed by comparing
the DGI gene scores corrected with step-wise regression analysis to
the corresponding gene scores corrected with traditional permu-
tation analysis, as the latter corrects for all confounding effects
(Figure 2; see Materials and Methods). The high correlation
between the regression-corrected gene scores, PGene0
g and the
permutation-corrected gene scores, PGene
g for all genes (Pearson’s
correlation coefficients, r=0.95; p,1e-30, Figure 2B) compared to
before correction (r=0.69, Figure 2A) indicates that only a small
fraction of the confounding effects on PBestSNP
g is not explained by
Table 1. Correlation between type 2 diabetes gene association scores and potential gene score confounders.
Mean across 1,000
permuted DGI GWA datasets DGI GWA study
Gene property
Correlation with ZBestSNP
(No correction)
Correlation with ZBestSNP
(No correction)
Correlation with ZGene0
(Regression correction)
Correlation with ZGene
(Permutation correction)
Gene size, kilobase (kb)
{ 0.26 0.25 20.03 0.01
# SNPs per kb
{ 0.38 0.39 20.05 20.02
# independent SNPs per kb
{ 0.32 0.31 20.07 20.001
# recombination hotspots
per kb
{
0.17 0.14 20.04 0.01
Linkage disequilibrium
units per kb*
0.22 0.19 20.06 0.02
Genetic distance,
centi-Morgan per kb
0.19 0.16 20.05 0.03
Pearson’s correlation coefficients were calculated between ZBestSNP, ZGene0
or ZGene and six different physical and genetic properties of genes. ZBestSNP is a vector of the
unadjusted best SNP per gene z-scores for all genes in the genome, ZGene0
is a vector of corrected gene z-scores using regression analysis for all genes, and ZGene is a
vector of corrected gene z-scores using phenotype permutation analysis for all genes. This was computed for 1,000 phenotype permutation data sets of the Diabetes
Genetics Initiative (DGI) GWA study and the actual DGI GWA study. Aside for gene size, all gene properties were converted to per kilobase (kb) units for each gene by
dividing by gene region size using the extended physical boundaries. All correlations between ZBestSNP and the six variables were statistically significant (mean p,2e-70
across 1,000 DGI permutations and p,1e-74 for the actual DGI study). Similar correlations were obtained for the five latter variables in Table 1 before normalizing to
gene region size (data not shown).
{These gene properties were significant in almost all 1,000 DGI GWA permutations tested under a step-wise multivariate linear regression model of ZBestSNP regressed
against the six gene properties (see Table S3).
*The linkage disequilibrium units per kb variable was significant under the regression model for about half of the permutations tested (Table S3).
doi:10.1371/journal.pgen.1001058.t001
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score ranks were compared (r=0.95 versus r=0.82; p,1e-30). A
comparison of the distributions of PGene0
g for different sized genes
using the permuted DGI data sets, demonstrates that the
regression-based correction has indeed removed the confounding
effect of gene size on PBestSNP
g (Figure S2).
We next compared the performance of the regression-based
correction to an analytical method previously proposed to correct for
the difference in number of (genotyped or imputed) SNPs per gene
(Sidak’s correction, [26,39]). The Sidak correction did not perform as
well as the regression-based correction (correlation with permutation-
corrected gene p-values: r=0.94, p,1e-30, but most gene p-values lie
below diagonal; see Figure S3 for details). This is probably due to the
method’s assumption of independence between all SNPs in a gene
region (eq. 4 in Materials and Methods). We then tested a
modification of Sidak’s correction proposed by Saccone et al. [40],
which assumes that about 50% of all SNPs in a given chromosomal
region are in high linkage disequilibrium (eq. 5 in Materials and
Methods). This correction was comparable to, or slightly better than
the regression method in the DGI test case (correlation with
permutation-corrected gene p-values: r=0.97, p,1e-30; Figure S3).
These results are in concordance with our findings that number or
density of SNPs is a dominant confounder on the best SNP per gene
score, PBestSNP
g (Table 1), and that correcting for linkage disequilib-
rium between SNPs is necessary.
For the current study we used the regression-based correction,
as it seems to behave equally well for different GWA studies (e.g.
DGI study and DIAGRAM+ meta-analysis; see Figure S4A, S4B),
while the modified Sidak’s correction (in particular its correction
for dependency between SNPs) may need to be adjusted for
specific studies, e.g. due to different SNP densities (see Figure S4C,
S4D). In any case, we later show that all GSEA results presented in
this work are robust relative to the correction method used.
From genes to gene sets: estimating power of MAGENTA
using simulations
After correcting for the majority of confounding effects on gene
association scores, we next combined gene scores at the level of gene
sets. We developed an approach similar to GSEA that tests whether
predefined sets of functionally related genes are enriched for genes
associated with a given complex disease or phenotype, more than
would be expected by chance (Figure 1D). Specifically, the GSEA
algorithm in MAGENTA tests for over-representation of genes in a
given gene set above a predetermined gene score rank cutoff. The
enrichment is evaluated against a null distribution of gene sets of
identical set size that are randomly sampled from the genome
multiple times (see Materials and Methods for details). The 95
th
percentile of all gene scores for a given GWA study or meta-analysis
was used here as the enrichment cutoff (see Figure S5 for cutoff
choice). Since subsets of genes in biological pathways are often
physically proximal in the genome [25], for each gene set, we
removedallbutonegenefromeachsubsetofgenesassignedthesame
best SNP, to prevent inflation of an enrichment signal due to
positional clustering of genes (assuming one gene per associated
variant).
We first evaluated the power (sensitivity) of the method to
identify enrichment of modest associations. We considered models
in which there is low detection power with single SNP analysis. We
Figure 2. Regression analysis corrects for majority of confounding effects on gene association scores in a genotype-independent
manner. The performance of a step-wise regression analysis approach in correcting for confounders on PBestSNP
g was evaluated against permutation
analysis correction, since the latter corrects for all confounders without requiring a priori knowledge of them. T2D gene association p-values were
plotted for all genes g in the genome (A) before gene score adjustment (PBestSNP
g ) and (B) after correction for confounders using regression analysis
(PGene0
g ), as a function of corrected gene p-values using phenotype permutation analysis (PGene
g ). The Diabetes Genetics Initiative (DGI) GWA study was
used for the analysis, since we had access to all individuals’ genotypes. PBestSNP
g is the association p-value of the best regional SNP for gene g before
correction (y-axis in A). To compute PGene0
g (y-axis in B), step-wise multivariate linear regression analysis was applied to PBestSNP
g against the first four
confounders listed in Table 1 (this approach does not require genotype data). The Pearson’s correlation coefficient (calculated between p-value
vectors before log transformation) increased significantly following the regression-based correction (from r=0.69 to r=0.95). The spread around the
diagonal (red line) also decreased following the regression correction (from a coefficient of variation (mean/std) of 1.13 to 0.56). The minimum PGene
g is
10
24 as the p-values were calculated based on 1,000 permutations for genes with PGene
g w0:01, and 10,000 permutations for genes with PGene
g ƒ0:01.
Some of the variation in the low p-value tail is due to having done only 10,000 permutations (PGene
g §0:0001), and some to limitations of the linear
regression method. Note that the four dots in (A) with PGene
g ƒ0:0001 contain ten overlapping dots that refer to four sets of 2–3 genes, each set
assigned the same PBestSNP
g . Gene association p-values are plotted on a 2log10(p-value) scale.
doi:10.1371/journal.pgen.1001058.g002
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assigned a causal SNP (referred to as causal genes), effect size of
the causal SNPs, and total number of causal genes. We performed
multiple computer simulations where small effect sizes were
randomly assigned to SNPs near different fractions of genes in a
given gene set, against a background of randomized DGI PSNP
i for
all SNPs i. Power was estimated for a given set of parameters as the
fraction of simulation runs in which gene set enrichment was
detected (described in Materials and Methods).
Figure 3 shows how the power of MAGENTA increases
proportionately with the fraction (Figure 3A) or number
(Figure 3B) of causal genes in three different gene set sizes, for a
set of parameters chosen to be consistent with the lower bound
effect size found to date in T2D and glycemic traits studied herein.
For a given number of causal genes, small gene sets are more
powerful; for a given fraction of causal genes, big gene sets have
more power. Furthermore, as may be expected, power increases
with the associated SNP effect size, and decreases with the total
number of causal genes in the genome (Figure S6).
Our simulations identified scenarios under which analysis of
GWA SNP data at the level of gene sets adds power in detecting
associations of small effect (e.g. odds ratio of 1.07 for an allele
frequency of 0.2–0.3 and sample size of 10,000 individuals [41])
compared to single SNP analysis. For example, consider a total of
100 causal genes in the genome each with an effect size, sufficient
to provide 1% power of detecting an association at the individual
SNP level at genome-wide significance. In this setting, MAGEN-
TA has 50% power of detecting enrichment if a given set of 1,000
genes (e.g. nuclear-encoded mitochondrial genes) contains ,3%
or 30 genes with a modest effect, when 100 genes (e.g. OXPHOS
genes) contain ,10% or 10 genes with a modest effect, or when 25
genes (e.g. on the order of the number of nuclear regulators of
mitochondrial genes) contain ,25% or 6 genes with a modest
effect.
Validation of MAGENTA on lipoprotein and lipid GWA
study meta-analyses
We next tested empirically the performance of MAGENTA on
LDL cholesterol, HDL cholesterol and triglyceride blood levels.
The molecular pathways involved in lipid and lipoprotein
metabolism are relatively well known, and many of the genes that
lie near the 30 SNPs so far reported to be associated with one or
more of these traits function in known processes related to lipid or
lipoprotein metabolism [34]. MAGENTA was applied to three
GWA meta-analyses [34], whose sample size (19,840 individuals) is
on the same order of magnitude as that of the largest available
T2D meta-analysis (DIAGRAM+) used below to test for
mitochondria-related associations with T2D. A total of 51
(partially overlapping) gene sets related to lipid, lipoprotein and
fatty acid metabolism were tested (defined by PANTHER [42] and
Gene Ontology [43] databases; see Materials and Methods). Of
these gene sets, we found biological processes related to lipid,
lipoprotein and fatty acid metabolism, binding and transport
activities, and triglyceride metabolism to be significantly enriched
for LDL cholesterol, HDL cholesterol and/or triglyceride
associations after Bonferroni correction (top gene sets are listed
in Table 2; full list in Tables S5, S6, S7). These results are robust
relative to the method used to correct for confounders on gene
association scores (Tables S8, S9, S10). Enrichment of LDL and
HDL associations in the lipid transport process has been
previously reported [25]. While most of the enriched processes
contain at least one gene near a validated lipid SNP, this analysis
also found enrichment in a pathway with unknown associations
(the fatty acid metabolic process). The fact that the enrichment
signals for many of the significant processes were still detectable
after removing the known lipid genes from the GSEA analysis,
suggests that some of the nominally significant associations in these
pathways may represent true associations of more modest effects
yet to be identified.
Figure 3. Estimating power of the GSEA algorithm in MAGENTA using computer simulations. We used simulations to assess the power
(sensitivity) of the gene set enrichment analysis (GSEA) algorithm in MAGENTA to detect enrichment of genes with modest effect sizes that are hard
to detect with single SNP analysis. Power is plotted as a function of fraction (A) or number (B) of causal genes of modest effect in gene sets of 25
(triangles), 100 (squares), or 1,000 (circles) genes. The modest effect size spiked into genes is equivalent to 1% power of detecting an association at
genome-wide significance using single SNP analysis. A total of 100 causal genes in the genome were assumed here. Randomized PSNP
i vectors from
case/control permutations of the DGI study were used as the background association values. Simulations were repeated 1,000 times for each unique
set of parameters. Power was calculated as the fraction of times the simulated gene set received a PGSEA
gs ,0.01. For specificity estimations we used
SNPs with no effect size, sampled from a null distribution that assumes no association. The false positive rate of the method (1-specificity) was
comparable to the p-value cutoff used (0.3–1.7%). Note the x-axis in both panels is on a log10 scale.
doi:10.1371/journal.pgen.1001058.g003
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Database Gene set
# genes
analyzed by
GSEA Nominal PGSEA
gs
Nominal PGSEA
gs without
known lipid genes
Genes near validated
lipid SNPs
Top lipid-related gene sets enriched for LDL cholesterol associations
GO, BP LIPID TRANSPORT 27 0.0001* 0.0352 APOE, LDLR
GO, BP LIPID HOMEOSTASIS 14 0.0005* 0.0204 APOE, PCSK9
GO, BP LIPOPROTEIN METABOLIC PROCESS 31 0.0010* 0.0038 LDLR
GO, BP LIPID METABOLIC PROCESS 291 0.0013* 0.0046 APOC1, APOC2, APOC4, LDLR
GO, BP FATTY ACID METABOLIC PROCESS 58 0.0019* 0.0024 -
GO, BP LIPID CATABOLIC PROCESS 36 0.0079 0.0078 -
GO, MF LIPID TRANSPORTER ACTIVITY 27 0.0090 0.0352 APOC4
GO, MF LIPOPROTEIN BINDING 18 0.0106 0.0466 LDLR
PANTHER FATTY ACID METABOLISM 88 0.0120 0.0112 -
GO, BP REGULATION OF LIPID METABOLIC
PROCESS
11 0.0140 0.0143 -
Top lipid-related gene sets enriched for HDL cholesterol associations
GO, BP TRIACYLGLYCEROL METABOLIC PROCESS 9 1e-6* 8.3e-5* APOC3, CETP, LPL, APOA5
GO, BP LIPID TRANSPORT 27 1e-6* 0.0023 ABCA1, APOA1, APOA4,
APOC3, CETP, LCAT
GO, MF LIPID BINDING 79 1.8e-5* 0.0036* APOA1, APOA4, CETP, APOA5
GO, BP LIPID HOMEOSTASIS 14 1e-5* 0.0012* ABCA1, APOA1, APOA4, CETP,
LCAT
GO, MF PHOSPHOLIPID BINDING 43 2.8e-5* 0.012 APOA1, APOA4, CETP, APOA5
PANTHER LIPID AND FATTY ACID TRANSPORT 99 4e-5* 0.0162 ABCA1, APOA1, APOA4,
APOC3, CETP, PLTP, APOA5
GO, BP LIPID METABOLIC PROCESS 287 6e-5* 0.0179 APOA1, APOA4, APOA5,
APOC3, CETP, HNF4A, LCAT,
FADS1, FADS2, LPL, MVK,
PLTP
GO, BP CELLULAR LIPID METABOLIC PROCESS 229 0.0003* 0.0548 APOA1, APOC3, CETP, LCAT,
FADS1, LPL
GO, MF STEROL BINDING 9 0.0004* 0.0435 APOA1, CETP
GO, BP LIPID CATABOLIC PROCESS 36 0.0006* 0.0068 APOA4, APOA5
GO, BP CELLULAR LIPID CATABOLIC PROCESS 33 0.005 0.0206 APOA5
GO, BP LIPID BIOSYNTHETIC PROCESS 87 0.0110 0.2327 APOA1, LCAT, FADS1, FADS2,
MVK
Top lipid-related gene sets enriched for triglyceride associations
GO, BP LIPID HOMEOSTASIS 14 0.0001* 0.0974 APOA1, APOA4, ANGPTL3
GO, BP TRIACYLGLYCEROL METABOLIC PROCESS 9 0.0008* 0.307 APOC3, LPL, APOA5
GO, MF LIPID TRANSPORTER ACTIVITY 25 0.0012* 0.3238 APOA1, APOA4
GO, BP LIPID TRANSPORT 26 0.0023 0.3154 APOA1, APOC3, ANGPTL3,
APOA4
GO, BP LIPOPROTEIN METABOLIC PROCESS 31 0.0044 0.4123 APOA1, APOA4, ANGPTL3
GO, BP PHOSPHOLIPID METABOLIC PROCESS 69 0.0081 0.0061 APOA1, FADS1, LPL
GO, BP LIPID CATABOLIC PROCESS 36 0.0083 0.0811 APOA4, APOA5, ANGPTL3
GO, BP GLYCEROPHOSPHOLIPID METABOLIC
PROCESS
42 0.0149 0.0036 APOA1
The most significant lipid-related biological gene sets with a gene set enrichment p-value of PGSEA
gs ,0.015 are presented using GWA meta-analyses of LDL cholesterol,
HDL cholesterol and triglyceride blood levels across a total of 19,840 individuals. Complete results for all 51 lipoprotein and lipid related pathways are presented in
Tables S5, S6, S7. GSEA p-values marked with an asterisk are significant under a conservative Bonferroni correction (each database was corrected separately due to
considerable overlap between gene sets across the different databases). The number of genes per gene set analyzed with MAGENTA in column three is after removing
genes without SNPs in their extended gene boundaries and after adjusting for chromosomal proximity between subsets of genes in a gene set (see Materials and
Methods). The fifth column contains GSEA p-values following exclusion of genes near validated SNPs for the relevant lipid trait (19 genes for LDL cholesterol, 20 genes
for HDL cholesterol and 19 genes for triglyceride levels; taken from Table 2 in [34]). The sixth column lists all genes near validated lipid SNPs (as of [34]) that fall in a
given gene set, including the genes removed due to adjustment for physical proximity in the genome. GO stands for Gene Ontology, BP for Biological Process, and MF
for Molecular Function.
doi:10.1371/journal.pgen.1001058.t002
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mitochondria-related gene sets
Having validated the utility of MAGENTA, we next used the
method to test whether mitochondria-related gene sets are
enriched for multiple genes that lie near common variants with
modest effects on T2D susceptibility. We tested three molecular
hypotheses based on the observations of reduced OXPHOS
activity and expression levels and fewer and smaller mitochondria
in diabetic muscle (described in the Introduction). The three
hypotheses were: DNA variants that alter the function of different
nuclear regulators of the OXPHOS pathway and/or other
mitochondrial processes are associated with T2D, variants that
cause core defects in OXPHOS activity that may result in
compensatory alterations of OXPHOS levels are associated with
T2D, and variants that affect other mitochondrial functions in
addition to the OXPHOS process are associated with T2D. To
test these hypotheses, we tested for enrichment of T2D
associations in the following three gene sets: a set of known
nuclear regulators of mitochondrial genes, the OXPHOS genes,
and all known nuclear-encoded mitochondrial genes. In parallel to
testing the relevance of these three sets to T2D, we explored their
possible associations (in non-diabetic individuals) with seven
specific glycemic traits that are risk factors for T2D (listed below).
We first analyzed a set of 16 nuclear regulators of mitochondrial
genes assembled based on the literature (listed in Table S11)
[35,44–48], using the latest DIAGRAM+ T2D GWA meta-
analysis of 8,130 cases and 38,987 controls from eight GWA
studies [36]. Since no individual mitochondria regulator was found
to date to be significantly associated with T2D at genome-wide
significance, we tested the hypothesis that common variants in
more than one regulator may affect T2D risk (possibly through
OXPHOS downregulation) in the diabetic populations analyzed
here. Upon applying MAGENTA to the set of nuclear regulators
we did not observe significant enrichment of T2D associations
compared to the genomic background of gene scores (Table 3;
PGSEA
gs =0.19; Quantile-quantile plot of gene p-values in Figure
S7A). The peroxisome proliferator-activated receptor delta,
PPARD (Entrez ID 5467) [44], received the best T2D gene p-
value, although it was not gene-wide significant (PGene0
g =0.0089).
The gene scores of the 16 known nuclear regulators of
mitochondrial functions are listed in Table S11.
Next, we tested for enrichment of T2D associations in a set of
91 autosomal OXPHOS genes (highlighted in the full list of
mitochondrial gene scores in Table S12). Using MAGENTA, no
significant enrichment of T2D associations was found among the
91 OXPHOS genes analyzed (Table 3; PGSEA
gs =0.47). A plot of
the OXPHOS T2D gene scores against an expected distribution
of gene scores is shown in Figure S7B.
Finally, we applied MAGENTA to 966 nuclear-encoded human
mitochondrial genes taken from the MitoCarta compendium
(,85% of all mitochondrial genes; see Materials and Methods)
[22]. We did not observe significant enrichment of T2D
associations for the whole set of mitochondrial genes either
(Table 3; nominal PGSEA
gs =0.91). A more detailed view of the
mitochondrial gene score distribution is shown in Figure S7C (see
Table S12 for a list of all mitochondrial gene association p-values).
While the above findings show no evidence of association
between relevant mitochondrial gene sets and T2D, these genes
could still display causal associations with specific intermediate
phenotypes linked to the disease. Support for this comes from
reported mitochondrial dysfunction in insulin-resistant individuals
[8]. Therefore, we tested the same three gene sets described above
for enrichment of associations with seven different glucose and
insulin-related traits characteristic of T2D, using GWA meta-
analyses of up to 46,186 non-diabetic individuals [37,38] (Soranzo
N. et al., unpublished data). The quantitative traits analyzed
include fasting levels of glucose and insulin, glucose and insulin
levels 2 hours following a 75-gram oral glucose tolerance test,
indices of b-cell function (HOMA-B) and insulin resistance
(HOMA-IR) [49], and glycated hemoglobin levels (HbA1C), which
reflect long-term plasma glucose concentrations (see Materials and
Methods).
No significant enrichment of genes associated with either of the
seven glycemic traits tested was observed for the set of nuclear
regulators of mitochondrial genes, the OXPHOS genes or the full
set of nuclear-encoded mitochondrial genes, after correcting for
multiple hypothesis testing (Table 4). Similar results were obtained
between all three gene sets and T2D or the seven glycemic traits
tested, using an alternative GSEA statistical test based on a rank-
sum test (see Materials and Methods and Table S13) or using an
alternative gene score correction method (modified Sidak’s
correction; Table S14), confirming the robustness of these results.
In summary, our gene set analysis of T2D and glycemic traits
did not provide support for many weak mitochondria-related
associations.
Discussion
We tested the open question of whether mitochondrial
dysfunction is a primary cause of type 2 diabetes (T2D) as
opposed to a secondary cause or an outcome of the disease. Using
a genetic approach, we comprehensively analyzed common
variant associations at the level of genes and gene sets, in search
for multiple modest genetic effects on T2D pathogenesis in a set of
nuclear regulators of mitochondrial activity, the oxidative
phosphorylation (OXPHOS) genes, or the full known set of
Table 3. Mitochondria-related gene sets are not enriched for associations with type 2 diabetes.
Gene set Total # genes
# genes without
SNPs in vicinity
# genes removed due to
physical clustering in
genome*
Effective
# genes
{ Nominal PGSEA
gs
Nuclear regulators of mitochondrial genes 16 0 0 16 0.1889
Oxidative phosphorylation genes 91 0 0 91 0.4722
Nuclear-encoded mitochondrial genes 966 11 70 885 0.9125
PGSEA
gs is the nominal gene set enrichment p-value for a given gene set gs, calculated here using the DIAGRAM+ T2D GWA study meta-analysis and an enrichment cutoff
that equals the 95th percentile of all gene p-values, PGene0
g .
{The effective number of genes is the number of genes analyzed after removing genes with no SNPs in their extended gene boundaries, and after correcting for
chromosomal clustering of subsets of genes in a gene set, i.e. removing all but one gene of each subset of genes assigned the same best local SNP p-value (*).
doi:10.1371/journal.pgen.1001058.t003
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of all mitochondrial genes). For this analysis, we developed a
modified GSEA approach applied to genetic association data (p-
values or z-scores), which we named MAGENTA. MAGENTA
was especially designed to exploit the increased power of meta-
analyses of multiple GWA studies. In the process we identified and
adjusted for confounders on gene scores and gene set enrichment
scores in the absence of genotype information. This method was
rigorously tested and evaluated using real and simulated GWA
data, and we demonstrate realistic scenarios in which this
approach could identify significant set-wide association signal that
is likely to be overlooked in individual SNP analysis.
Identifying and correcting for confounders on SNP to
gene association p-values
In testing for possible confounding effects, we observed that the
unadjusted most significant SNP per gene p-value is affected by
several gene properties, most notably physical gene size and
number or density of SNPs per gene, and the genetic properties:
number or density of SNPs across a gene that are in linkage
equilibrium to each other and number or density of recombination
hotspots that span a gene. While gene size and number of SNPs
per gene have been recently reported to be correlated with the
unadjusted best SNP p-value [23,25,33], we have quantitatively
demonstrated the magnitude of these and linkage-based effects
using randomized GWA study data, confirming their potential
confounding effects. We show that large genes tend to receive a
more significant score than small genes by chance (Figure S2).
By using regression analysis to adjust the gene scores for the
confounding effects we identified, we provide a viable approach to
determine gene association p-values in the absence of genotype
data, which should prove useful for mining large GWA study
meta-analyses or other types of GWA studies where only variant
association statistics are available. Using the Diabetes Genetics
Initiative (DGI) study, we showed that our correction accounts for
most of the confounding effects on the most significant SNP score
and yields gene scores that are much more accurate than those
obtained without correction [31]. Notably, this regression
approach and the DGI permutation system can be used to
identify and adjust for confounders on other types of SNP to gene
scores (e.g. considering best SNP per LD block [25,33] or the set–
based test in PLINK http://pngu.mgh.harvard.edu/,purcell/
plink/anal.shtml#set). While in the current work we focus largely
on developing a gene set approach following gene score correction,
we envisage that the corrected gene p-values might be valuable in
future gene-centric studies, allowing one to properly weigh specific
genes (e.g. small genes) that may otherwise be missed.
Power of MAGENTA evaluated using simulated and true
association data
Using computer simulations, we show that MAGENTA has
considerable power (i.e. sensitivity) in detecting multiple modest
effects relative to traditional single SNP analysis for a range of
parameters. For example, for a gene set size of 100 genes, our
method has 50% power of detecting enrichment when ,10 genes
have weak effects (that are equivalent to 1% detection power at
single SNP level) versus 10% power of detecting only one of the 10
genes in single SNP analysis. By applying MAGENTA to GWA
scan meta-analyses for LDL cholesterol, HDL cholesterol and
triglyceride levels, we confirmed the method’s ability to pick out
relevant biological processes. We note that the nominal MAGEN-
TA p-values for these positive controls were not exceedingly low
(on the order of 10
22 to 10
26), emphasizing the limited power of
the gene set approach. Our simulations allowed us to provide
quantitative estimates of these limitations, and indications of
possible limiting factors. For example, we found that power levels
increase considerably with gene set size, fraction of causal genes in
a gene set, and effect size of associated SNPs, and decrease with
total number of causal genes in the genome. Similar trends, as a
function of effect size and fraction of causal SNPs, have been
shown with other types of GSEA methods that test for enrichment
in SNP sets across pathways [32,33].
No evidence for a causal role of mitochondrial
dysfunction in T2D
Despite a large sample size, comprehensive gene lists, and a
calibrated statistical method, we did not find evidence that
common variants in proximity to ,1,000 known nuclear-encoded
mitochondrial genes contribute to T2D susceptibility. Similarly,
we found no indication of significant associations between variants
near these genes and intermediate physiological phenotypes
related to T2D. Simulations of MAGENTA performance suggest
that if there is a genetic contribution it is small - probably no more
than 2–4% of nuclear-encoded mitochondrial genes (,20–40
genes) harbor common variants of modest effect (e.g. an odds ratio
of ,1.07 for allele frequency of 0.2–0.3 and sample size of 10,000
individuals) on T2D risk. This number may vary to some extent
depending on the actual effect sizes and total number of causal
genes for the disease (see Figure S6). As of the latest T2D meta-
analysis used here (DIAGRAM+), three mitochondrial genes (IDE,
C8orf38 (Entrez ID 137682), and ACADS (Entrez ID 35)) lie near
validated T2D SNPs amongst other genes in the interval [20], but
a causal connection for these genes with T2D has not yet been
shown.
Although the expression of multiple OXPHOS genes is
downregulated in skeletal muscle of patients with diabetes [9],
and OXPHOS activity is reduced in diabetic and insulin-resistant
individuals, we did not find evidence that OXPHOS genes lie
Table 4. Mitochondria-related gene sets are not enriched for
associations with type 2 diabetes-related glycemic traits.
Glycemic trait
Nuclear-encoded
mitochondrial
genes PGSEA
gs
OXPHOS
genes PGSEA
gs
Nuclear
regulators of
mitochondrial
genes PGSEA
gs
Fasting glucose 0.1255 0.8354 0.5568
Fasting insulin 0.2489 0.9490 0.1878
2 hour glucose 0.3026 0.6696 1.0000
2 hour insulin 0.2900 0.9462 1.0000
HOMA-IR 0.6567 0.9429 0.1855
HOMA-B 0.7678 0.8375 0.5661
HbA1c 0.0179
{ 0.9901 1.0000
PGSEA
gs is the nominal gene set enrichment p-value for gene set gs computed for
each glycemic trait separately. The enrichment cutoff calculated for each
phenotype is the 95th percentile of all gene p-values computed from the
corresponding GWA study meta-analysis. HOMA-IR is an index for insulin
resistance, HOMA-B is an index for ß-cell function, and HbA1c represents
glycated hemoglobin concentrations, which is a measure of long-term plasma
glucose concentrations.
{Not significant after Bonferroni correction (most stringent cutoff p,0.002
given 3 gene sets and 8 traits; a less stringent cutoff, p,0.0083 correcting for 3
gene sets and 2 traits due to correlation between the glucose and insulin-
related traits).
doi:10.1371/journal.pgen.1001058.t004
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traits. This is consistent with a previously reported pathway
analysis of one of the T2D GWA studies included in the
DIAGRAM+ meta-analysis [27]. Lack of enrichment in the
OXPHOS genes suggests that either the changes in expression
are an effect and not a cause of diabetes, or that one or few
regulators of OXPHOS [35] contain yet undetected rare or
common variants, or inherited epigenetic changes associated with
T2D or a related phenotype. Since, to date, there is no conclusive
evidence for a strong association of any of the 16 known nuclear
regulators of mitochondrial genes to T2D, we tested whether
several regulators might harbor common variants with modest
effect on T2D risk in the population. In our analysis we could not
find strong support for this possibility. Our simulations suggest
that we would have considerable power to detect enrichment if at
least ,9 OXPHOS genes or at least ,3 nuclear regulators were
modestly associated with T2D or a related trait. While specific
genes ranked high among the 16 regulators (but not at gene-wide
significance), such as GABPA (the GA binding protein transcrip-
tion factor, alpha subunit) [50] with respect to T2D associations
or SIRT1 (sirtuin, silent mating type information regulation 2
homolog 1; Entrez ID 23411) [51,52] with respect to fasting
insulin levels and measures of insulin resistance and ß-cell
function, our statistical tests do not constitute a proof of their
involvement in T2D. Future gene-centric approaches using our
corrected gene scoring system or others may be used to examine
more closely these and similar instances.
We note that while lack of enrichment of associations with T2D
and related-traits does not provide support for a causal connection,
it does not eliminate the possibility that individual genes could still
be found to have a genetic effect and thus be instrumental to T2D
predisposition. For example, the absence of enrichment in the
OXPHOS genes does not disprove the association to T2D of one
of its genes, C8orf38 (an assembly factor in Complex I, the first
complex in the mitochondrial electron transfer chain; Entrez ID
137682) [22], which lies near a validated T2D SNP found in the
recent DIAGRAM+ T2D meta-analysis [36], but it does not
provide further support for C8orf38 being causal.
Limitations of MAGENTA and other GSEA approaches
applied to variant association data
Our finding that specific mitochondria-related gene sets
functionally implicated in T2D are not enriched for associations
could be due to several reasons, of potential relevance also to the
study of other diseases: (i) The fraction of causal genes in the
given gene set, while considerable, may not be significantly higher
than the total fraction of causal genes in the genome (especially
relevant to gene permutation analysis); (ii) The causal variants
may be spread across a large number of biological processes or
there may be allelic heterogeneity in the population, making it
hard to detect clustering of associations into pathways; (iii) Causal
genes for certain phenotypes may cluster in small pathways,
which are more sensitive to individual gene score fluctuations
than large pathways; (iv) The relevant pathways or sets of
functionally related genes may have not yet been tested; (v) By
considering only variants within a given distance around each
gene, potential signals from more distant transcriptional regula-
tory elements, such as enhancers or epigenetic marks, might be
missed; future genome-wide maps of regulatory elements may be
used to generate a discontinuous and precise map of potential
causal regions per gene; and finally (vi) Rare variants were not
tested, but when the data are available the MAGENTA
framework can be applied to this class of variants.
General applications of MAGENTA and other GSEA
approaches to GWA studies
Certain common diseases and traits may be more amenable to
GSEA approaches than others, depending on their genetic
architecture. In addition to identifying new biological pathways
or processes associated with disease risk or trait variation, GSEA
methods, such as MAGENTA, may provide predictions for new
disease or trait genes of modest effects (top ranked gene scores in
enriched gene sets). Such joint analysis of SNPs (or other types of
variants) at the gene and gene set levels should be most useful for
detecting associations in a narrow range of nominal significance
levels (between noise levels, e.g. p,0.1, and SNP replication cutoff,
e.g. p.,0.0001), a range that has been shown to contain
associations of small effect in polygenic disorders [53]. The GSEA
approach may also help prioritize potential causal genes in
validated association regions that contain multiple genes.
Our method which explicitly accounts for important confounders
on the association scores of genes (e.g. gene size) and gene sets (e.g.
positional effects of genes in a gene set) in the absence of genotype
data, and that provides upper-bound estimates of number of
associations per gene set, should provide accurate tests of gene sets
of interest, especially for analyzing large GWA scan meta-analyses.
MAGENTA can also be applied to sets of genetic loci other than
genes, such as linkage disequilibrium blocks. More generally, such
GSEA approaches may be valuable for gene and pathway analysis of
other types of genetic studies that deal with multiple measurements
per gene, such as exon resequencing in case-control studies.
Materials and Methods
Ethics statement
The study constitutes a secondary analysis of genetic data
derived from de-identified samples, and thus has an IRB
exemption.
GWA studies and meta-analyses analyzed
Two type 2 diabetes (T2D) GWA studies were analyzed in this
work. The first is the Diabetes Genetics Initiative (DGI) GWA
study, used for method development purposes. 381,099 genotyped
SNPs were analyzed using only the population-based individuals,
that consist of 1,022 diabetic patients and 1,075 matched control
individuals (a total of 2,097 individuals) [17]. The second study is
the most recent T2D GWA meta-analysis (DIAGRAM+) [36],
used to test the mitochondrial-diabetes hypothesis with MAGEN-
TA. The meta-analysis was performed across eight GWA studies,
with a total of 8,130 diabetic patients and 38,987 non-diabetic
controls (47,117 individuals total, effective sample size n=22,044),
and 2,255,856 genotyped and imputed autosomal SNPs.
The GWA study meta-analyses of seven diabetes-related
glycemic traits analyzed in this work were part of the Meta-
Analyses of Glucose and Insulin-related traits Consortium
(MAGIC) [37,38] (Soranzo N. et al., unpublished data). These
seven traits include fasting glucose concentrations, fasting insulin
concentrations, 2-hour glucose and 2-hour insulin concentrations
after an oral glucose tolerance test, indices of b-cell function
(HOMA-B) and of insulin resistance (HOMA-IR), calculated from
fasting glucose and insulin measures using homeostasis model
assessment [49], and HbA1C (glycated hemoglobin) levels. The
meta-analyses for fasting glucose, fasting insulin, HOMA-B and
HOMA-IR were performed on 20 or 21 GWA studies with a total
of 36,466 to 46,186 non-diabetic individuals [37,38], the meta-
analyses for 2-hour glucose and 2-hour insulin were performed
across 9 studies and a total of 15,234 individuals [37,38], and the
meta-analysis for HbA1C was performed across 23 cohorts with a
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unpublished data). The total number of genotyped and imputed
autosomal SNPs analyzed in these seven meta-analyses varied
between 2,323,569 and 2,748,910 SNPs.
To test the performance of MAGENTA on traits whose
underlying biology has been well studied, we analyzed three GWA
study meta-analyses of low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol and triglyceride blood
levels [34]. All three meta-analyses were performed with 19,840
individuals from seven GWA studies, on 2,552,754, 2,552,580 and
2,552,773 genotyped and imputed SNPs for the LDL cholesterol,
HDL cholesterol and triglyceride meta-analyses, respectively.
The association tests of all the aforementioned GWA studies were
performed at the singleSNP level, assuming an additive allelic model.
The individuals in all GWA studies are of European descent.
Meta-Analysis Gene-set Enrichment of variaNT
Associations (MAGENTA)
Step 1: Mapping SNPs onto genes. A list of 26,914 human
gene transcripts was downloaded from the UCSC Genome
Browser (http://genome.ucsc.edu/) in RefFlat format based on
the human March 2006 (hg18) assembly. In the current study,
18,434 unique genes were used (17,680 on autosomes, and 754 on
sex chromosomes), after filtering out genes with two or more
transcripts that lie more than 1Mb apart on the same chromosome
or that lie on separate chromosomes. All the genotyped or imputed
SNPs that lie within an added physical distance upstream or
downstream to a gene’s most extreme transcript start and end sites
of all its known splicing isoforms (intron and other non-coding
sequences included) were assigned to each of the 18,434 genes. For
gene set enrichment analysis of T2D, glycemic traits, and lipid and
lipoprotein traits we used 110 kb upstream to the gene’s most
extreme transcript start site and 40 kb downstream to the gene’s
most extreme transcript end site. These boundaries were chosen as
they represent the 99
th percentile of the distances of cis-eQTLs
from their adjacent gene’s transcript start and end sites. This is
according to a comprehensive genome-wide analysis of putative
functional regulatory elements (cis-eQTLs) using expression data
from human lymphoblastoid cell lines [54]. These boundaries
were chosen in attempt to capture association signals from
proximal regulatory regions, in addition to the coding region.
For the analysis of the DGI GWA study and the DGI
permutations (used for method development purposes), 650 kb
was used, as these analyses were done before the Veyrieras et al.
publication [54]. In the future, when transcriptional elements are
comprehensively characterized for all genes in the genome, a
discontinuous and more precise map of regulatory regions for each
gene could be used for assigning SNPs to genes.
Steps 2 and 3: Scoring genes based on SNP association
scores and correcting for confounders. For each gene g in
the genome we calculated a score, PGene0
g that is the probability
that the gene is associated with a given disease or trait. In
computing this score we corrected for the confounding effects of
physical and genetic properties of genes on the gene p-value.
Step 2. The scoring metric used here is as follows: For each gene
g, the minimum GWA p-value of all SNPs with index i that fallwithin
t h ee x t e n d e dg e n eb o u n d a r i e s( s e eS t e p1 )i sc h o s e n ,PBestSNP
g :
PBestSNP
g ~ min
i[Ig ðÞ
fPSNP
i gð 1Þ
where I(g) is the set of indeces of SNPs whose chromosome positions
fall between the extended gene boundaries. PSNP
i is the association p-
value for SNP i calculated in a GWA study or meta-analysis (see
GWA studies and meta-analyses section). A z-score ZBestSNP
g is then
computed based on PBestSNP
g for each gene g,u s i n gam e a no f0a n d
standard deviation of 1, assuming a normal distribution. PBestSNP
g
should be most powerful for genes that contain one major target
regionor haplotypewithpotentialcausal mutationsin or around their
coding sequence. Other SNP to gene scoring metrics can be used
here.
Step 3. To correct for confounding effects on PBestSNP
g we
regressed out the effect of several potential confounders from
PBestSNP
g , using step-wise multiple linear regression analysis [55].
The method begins by regressing out the effect of a variable with high
correlation with the gene score; it then adds the next significant
variable, and evaluates whether the added variable should be kept
and whether any existing variables should be eliminated from the
regression model. The latter step is repeated until all variables are
considered. A variable was added at p,0.05 and removed at p.0.1.
The step-wise nature of this method should account for correlations
between the variables. We initially tested this model using 1,000 DGI
GWA permutations and six gene properties as potential confounders
(predictor variables). In this case, step-wise multivariate linear
regression was applied to ZBestSNP
g using the full list of genes, and
the coefficients a, b, d, c, g,a n dk were estimated such that for every
gene g one can calculate:
ZBestSNP
g ~a:dgzb:ngzd:ugzc:hgzg:cgzk:lgzrg ð2Þ
where rg is the residual of the association score for gene g that cannot
be explained by the effects of the predictor variables considered. After
the regression a corrected gene z-score, ZGene0
g c a nb ew r i t t e na s
follows:
ZGene0
g ~ZBestSNP
g {a:dg{b:ng{d:ug{c:hg{g:cg{k:lg ð3Þ
Ac o r r e c t e dg e n ep-value PGene0
g is calculated from ZGene0
g assuming a
normal distribution and a mean of 0 and standard deviation of 1
(reasonable approximation but not perfect, in particular for the less
significant values of PGene0
g ; see Figure S8). Of all six gene properties
tested, only the genetic distance, cg, was not significant (p.0.05) in
most of the DGI permutations subjected to the regression analysis
(Table S3), and hence g~0 w a su s e df o ra l la n a l y s e si nt h i sp a p e r .
Similar GSEA results were obtained for all gene sets and traits
analyzed in this paper when only the first four variables listed in
Table 1 (significant in almost all 1,000 DGI permutations tested; see
Table S3) were used for the regression-based correction of gene scores
(k~0 and g~0) (data not shown).
This step-wise linear regression approach can be used to adjust
for confounders on other types of variant to gene scoring metrics,
and an appropriate set of potential confounders can be identified
using the DGI permutation system described below.
Comparison to analytical gene score correction
methods. The regression-based method was compared to
Sidak’s combination test, also known as Sidak’s correction [26],
and to a modified version of Sidak’s correction [40]. The corrected
gene p-value, PGene0
g based on Sidak’s correction is defined as follows
for gene g:
PGene0
g ~1{ 1{PBestSNP
g
 N
ð4Þ
where PBestSNP
g , defined in eq. 1, is the most significant SNP p-value
for gene g, and N is the total number of SNPs with available
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[40] uses (N+1)/2 as the exponent to adjust for linkage disequilibrium
between regional SNPs, assuming ,5 0 %o fS N P si nag i v e ng e n o m i c
region are in tight linkage disequilibrium:
PGene0
g ~1{ 1{PBestSNP
g
 Nz1
2 ð5Þ
Step 4: Gene set enrichment analysis of genome-wide
association data. To test for over-representation of genes with
modest genetic effects on a complex disease or trait in predefined
sets of genes, we developed a gene set enrichment analysis (GSEA)
algorithm that is applied to gene association p-values adjusted for
confounding effects. This algorithm does not require the genotypes
of individuals in the association scans in order to estimate gene set
enrichment significance. Our GSEA test was inspired by the
original GSEA algorithm applied to expression data [9,24], more
recently modified for SNP association data [23,25,28,32], but uses
a different statistical test. The null hypothesis is that the gene
association score ranks of all genes with index g that belong to a
given gene set gs are randomly distributed. The alternative
hypothesis is that there is an over-representation in gene set gs of
gene score ranks above a given rank cutoff compared to multiple
random gene sets of identical size that were randomly sampled
from all genes in the genome.
The specific steps of the GSEA statistical test employed here are
as follows: (i) Corrected gene association p-values were calculated
for all genes in the genome, based on a given GWA study or meta-
analysis. In this study, we used the corrected gene p-value, PGene0
g
as it can be computed for studies where individuals’ genotypes are
not available. If genotype data are available, the gene score PGene
g
can also be computed (see above for PGene0
g definition and section
below for PGene
g definition). (ii) Several types of genes were
removed from gene sets. Genes with no SNPs in their extended
gene boundaries were not included in the analysis. In addition, for
each subset of genes in a given gene set that were assigned the
same most significant SNP, all genes but one were removed from
the analysis; the gene with the most significant gene score was
retained. This was done to eliminate potential inflation of gene set
enrichment significance due to two or more genes in a gene set
that are physically proximal along the chromosome and hence
may capture the same association signal (assuming one causal gene
per associated locus). This yielded an effective number and set of
genes that was used for the next steps of the GSEA test. (iii) For
each gene set gs the fraction of genes with PGene0
g ,PCutoff was
recorded (denoted here as the ‘leading edge fraction’), where
PCutoff is a predetermined gene p-value cutoff, defined as a given
percentile of all gene p-values in the genome. PCutoff is specific for
a given GWA study or meta-analysis. In this study, we used
PCutoff =95
th percentile of PGene0
g for all genes g in the genome, as
it gave the optimal power of five cutoffs tested (99
th,9 5
th,9 0
th,
75
th, and 50
th percentile of all gene p-values) with power
simulations (see Figure S5 and Simulations section below). (iv)
Finally, a nominal GSEA p-value, PGSEA
gs was calculated for each
gene set gs, defined as the fraction of randomly sampled gene sets
of identical set size, whose leading edge fraction is equivalent to or
larger than the observed leading edge fraction of gene set gs. The
null distribution of leading edge fractions was generated for each
gene set gs by randomly sampling 10,000 gene sets from the
genome (or more when PGSEA
gs ,10
24) that are of identical set size
to the effective size of gene set gs (after adjusting for physical
clustering in the genome of subsets of genes in each randomly
sampled gene set separately, as described above). Genes in gene set
gs were not excluded from the random sampling procedure. (v) To
correct for multiple hypothesis testing, Bonferroni correction was
used (i.e. significance cutoff p=0.05 divided by the number of
hypotheses tested). This may be too stringent when a large number
of gene sets is tested due to overlap of genes between the different
gene sets.
To test the robustness of our GSEA results for the mitochon-
dria-related gene sets, we applied an alternative GSEA statistical
test, based on a one-tailed Mann-Whitney rank-sum test (Table
S13). First, for each gene set gs we calculated a one-tailed rank-sum
p-value that tests the alternative hypothesis that PGene0
g ranks for all
genes in gene set gs are skewed towards high ranks compared to
the gene score ranks of the rest of the genes in the genome.
Second, a similar one-tailed rank sum p-value was calculated for
10,000 random gene sets of identical size that were randomly
sampled from the genome and adjusted for chromosome clustering
of subsets of genes in the gene set. Finally, a rank-sum based
GSEA p-value, PGSEA
gs was computed for gene set gs as the fraction
of randomly sampled gene sets whose rank-sum p-value was
equivalent to or more significant than the rank-sum p-value of the
tested gene set gs.
Identifying confounders on gene association scores
The potential confounding effects of six gene properties on the
most significant SNP p-value, PBestSNP
g for all genes g were
examined using 1,000 DGI study permutations, described below.
The gene features tested include: (1) Physical gene size for gene g,
dg, defined as the distance in kilobase (kb) units between the most
extreme transcript start and end sites of all isoforms of a given gene
(including introns), plus an added distance. For the extended
boundaries of 2110kb/+40kb used for the mitochondrial and lipid
analyses, 150 kb were added, and for the 650 kb boundaries used
for method development purposes, 100 kb were added; (2)
Number of genotyped and imputed (if available) SNPs per kb
for each gene g, ng; (3) Estimated number of independent SNPs
(that are in approximate linkage equilibrium with each other) per
kb for each gene g, ug. This was calculated using the –indep option
in PLINK that prunes SNPs based on the variance inflation factor,
VIF (http://pngu.mgh.harvard.edu/,purcell/plink/summary.
shtml#prune; default parameters were used). The genotypes of
the CEU population from HapMap version 19 were used, since
the GWA samples analyzed in this work are of European
descendent. This yielded 310,399 independent autosomal SNPs;
(4) Number of recombination hotspots spanning gene g per kb, hg.
Recombination hotspot positions were taken from [56]; (5)
Genetic distance of each gene g, cg in centi-Morgan (cM) per kb
units calculated based on a fine-scale map of recombination rates
[56]; and (6) Linkage disequilibrium units (LDU) per kb for each
gene g, lg, calculated based on an LDU map downloaded from
http://cedar.genetics.soton.ac.uk/pub/PROGRAMS/LDMAP
[57]. All variables were calculated based on the extended gene
boundaries. All variables but gene size, dg were transformed to ‘per
kilobase’ units: variables ng, ug, and hg, were divided by dg, and
variables cg and lg were divided by the physical distance between
the most extreme genetic markers within the gene boundaries for
which genetic distance or LDU data were available. All six
variables showed a significant correlation with PBestSNP
g for all
genes g, using 1,000 DGI study permutations, both before and
after normalization to gene region size.
Permutation analysis of Diabetes Genetics Initiative GWA
study
We used the Diabetes Genetics Initiative (DGI) GWA study
[17] as a test case for developing MAGENTA, as we had access to
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meta-analyses analyzed in this paper where we do not have access
to genotype data). The analysis was done only on the population-
based samples of the DGI study - 1,022 cases and 1,075 controls
that were matched for age, gender, body mass index and region of
origin. Specifically, the T2D case/control labels were randomly
permuted 1,000 times between individuals from the same
collection center and the same gender. A genome-wide association
test (logistic regression) that assumes an additive allelic model (1
degree of freedom) followed by a genomic control (adjustment for
lambda larger than 1) was then applied to each of the 381,099
genotyped SNPs across the 1,000 permutations, resulting in an
association p-value, PSNP
i for each SNP i and each permutation.
PBestSNP
g was calculated for all genes in the genome, across the
1,000 DGI permutations. A gene p-value adjusted for confounding
effects with permutation analysis, PGene
g was then calculated for
each gene g in the genome. PGene
g is defined as the fraction of
permutations whose PBestSNP
g is equal to or lower (more significant)
than the observed DGI PBestSNP
g . We performed an additional
10,000 case/control permutations for SNPs within 650 kb around
genes with PGene
g ƒ0:01 to increase resolution. Genes with
PGene
g v10{4 were assigned PGene
g ~0:99:10{4.
The gene score vectors before correction (PBestSNP) calculated
for the 1,000 DGI permuted data sets were used to quantify the
correlation between six gene properties of potential confounding
effects on PBestSNP
g and PBestSNP
g (Table 1). The permutations were
also used to evaluate which of the correlated gene properties had a
significant confounding effect on PBestSNP
g based on a step-wise
multivariate linear regression model (Table S3). The resulting
significant confounders were used in all gene set analyses presented
in this study. To assess the performance of our regression-based
correction of confounders on PBestSNP
g , Sidak’s correction and a
modified Sidak’s correction, we compared the corrected gene p-
values, PGene0
g to the corresponding gene p-values corrected with
permutation analysis, PGene
g for all genes g, using the actual DGI
study. Permutation analysis was used as the gold standard for
adjusting for confounders on SNP to gene scores as it generates
gene-specific null distributions while maintaining the physical and
genetic structure of SNPs across gene regions. This enables
correcting for all possible confounding effects on gene association
scores without requiring a priori knowledge of the confounders.
The performance of our regression-based correction, Sidak’s
correction and a modified Sidak’s correction were evaluated by
comparing the Pearson’s correlation coefficient between PGene0
g
and PGene
g to the correlation coefficient between the unadjusted
gene score, PBestSNP
g and PGene
g for all genes g in the genome.
The permuted PSNP
i for all SNPs i were also used for power
simulations described in the next section.
Simulations used to estimate sensitivity and specificity of
MAGENTA
We developed a simulation framework to evaluate the power of
MAGENTA to identify enrichment of multiple associations for
which we have low detection power with single SNP analysis.
SNPs with a small effect size were randomly spiked into varying
numbers of genes (referred to as causal genes) in pre-specified gene
sets (one SNP per gene), and into genes outside the gene set,
maintaining the total number of causal genes in the genome. The
simulations were performed on a background of randomized SNP
association p-values, PSNP
i for all SNPs i in the genome, generated
with phenotype permutations of the DGI study (see section above).
For each set of parameters tested, 1,000 simulation runs were
performed. In each simulation run, the genes representing a
simulated gene set of a given size were randomly chosen from the
genome, and the various fractions of genes assigned a SNP of small
effect size were also randomly chosen from all genes in the gene
set. The remaining number of causal SNPs was randomly assigned
to genes outside the gene set. The small effects were randomly
assigned to SNPs within the 650kb extended gene boundaries (see
above for boundary definition). To eliminate artifacts that could
arise from using one specific vector of permuted PSNP
i , each
simulation run was done on a different GWA study permutation
background that was randomly chosen from 1,000 different DGI
phenotype permutations. For each of the 1,000 simulation runs,
gene p-values corrected with multivariate regression analysis (see
above), PGene0
g were calculated for all genes g in the genome. The
GSEA algorithm in MAGENTA was then applied to the
simulated gene set with a given fraction of causal genes of weak
effect. Finally, GSEA power (i.e. sensitivity) was estimated as the
fraction of 1,000 spike-in simulations whose gene set enrichment p-
value, PGSEA
gs exceeded a given significance level (in this study
PGSEA
gs #0.01, a suitable cutoff for the few hypotheses tested in the
mitochondrial gene set analysis). The power does not decrease
significantly when a more stringent cutoff is used: PGSEA
gs #0.001
(Figure S9).
The parameters used in the simulations are: (i) Gene set size of
25, 100 or 1000 genes; (ii) Fraction of genes in a gene set that got
assigned a SNP with a modest effect size: 0 (negative control), 1%,
5%, and 10%, 20%, 30%, 40%, 50% and 60%; (iii) The small
effect size of each spiked-in SNP was estimated by randomly
sampling from a noncentral chi-square distribution with one
degree of freedom (assuming an additive allelic test). The non-
centrality parameters (NCP) used were: NCP=0 for estimating
specificity or false positive rate of our GSEA method, NCP=2.5
for a very weak effect size (equivalent to 1% power of detection at
p#1e-4 using single SNP analysis; e.g. odds ratio of 1.03–1.04 for
an allele frequency of 0.2–0.3 and sample size of 10,000
individuals [41]; Figure S6A), and NCP=10 for a modest effect
size (equivalent to 1% power of detection at genome-wide
significance (p#5e-8) using single SNP analysis; e.g. odds ratio
of 1.07 for an allele frequency of 0.2–0.3 and sample size of 10,000
individuals [41]; Figure 3); and (iv) A total of 100 (Figure 3) or 500
(Figure S6B) causal genes in the genome. The chi-square test
statistic was then converted to a z-score by taking the square root
of the chi-square test statistic. Parameters were chosen in attempt
to reflect what we know about the genetic architecture of complex
diseases and traits.
This simulation framework was also used to choose an optimal
gene score enrichment cutoff, PCutoff for our GSEA algorithm.
Five cutoffs were tested: 99
th,9 5
th,9 0
th,7 5
th, and 50
th percentile
of all gene p-values for two effect sizes: NCP=2.5 and NCP=10,
assuming a total of 100 causal genes in the genome. A PCutoff
equivalent to the 95
th percentile of PGene0
g for all genes g in the
genome yielded the optimal power, when considering power plots
for both effect sizes (Figure S5). The 75
th percentile cutoff
performed a bit better than the 95
th percentile cutoff for very weak
effects (NCP=2.5; Figure S5B), especially when assuming a total
of 500 causal genes (data not shown). Hence, the 75
th percentile
cutoff could be used for diseases or traits that are highly polygenic
with many associations of weak effects.
Gene sets analyzed with MAGENTA
Mitochondria-related gene sets. Of the 1,012 unique
human mitochondrial genes described in MitoCarta [22], we
analyzed 966 autosomal mitochondrial genes. This number was
obtained after removing 13 genes encoded by the mitochondrial
DNA and 31 mitochondrial genes that lie on the X and Y
chromosomes, as they were not analyzed in the GWA studies and
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removed, as they were absent from the human gene list used for
our analyses. For the DIAGRAM+ T2D meta-analysis, the
effective gene set size of all mitochondrial genes was 885 genes,
as 11 genes did not have any genotyped or imputed SNPs within
their extended gene boundaries (110 kb upstream and 40 kb
downstream to the most extreme transcript boundaries) and 70
genes were removed following physical proximity adjustment
described in the GSEA section. There are 110,060 unique SNPs
that fall within the gene regions of the 966 nuclear-encoded
mitochondrial genes, based on the DIAGRAM+ meta-analysis
(4.9% of all SNPs).
A list of 91 oxidative phosphorylation (OXPHOS) genes out of
the 966 autosomal, mitochondrial genes was manually curated
(marked in Table S12). This list does not include 12 OXPHOS
genes encoded by the mitochondrial DNA and 3 genes on
chromosome X. There are 9,693 SNPs that fall within the gene
regions of the 91 OXPHOS genes based on the DIAGRAM+
meta-analysis (0.4% of all SNPs).
A set of 16 known nuclear transcriptional regulators of
mitochondrial functions was assembled based on the literature
[35,44–48] (Table S11). All mitochondria regulators had SNPs in
their extended gene boundaries using the DIAGRAM+ meta-
analysis.
Lipid- and lipoprotein-related gene sets. We tested 15
biological processes related to lipid, fatty acid and steroid
metabolism defined by the PANTHER classification method
(http://www.pantherdb.org/) [42], and 36 gene sets related to
lipid, lipoprotein and fatty acid metabolism defined by Gene
Ontology [43], which include 7 molecular functions and 29
biological processes. The Gene Ontology gene sets were taken
from the Molecular Signatures Database (MsigDB, http://www.
broad.mit.edu/gsea/msigdb/collections.jsp).
In this paper we analyzed gene sets with an initial gene set size
of 10 genes or more.
Software
MAGENTA is freely available for use at http://broadinstitute.
org/mpg/magenta.
Supporting Information
Figure S1 Cumulative distribution of mitochondrial and non-
mitochondrial gene scores before and after adjustment for
confounders. The cumulative p-value distributions are plotted for
the most significant SNP T2D association p-value within each
gene’s extended boundaries (A) before and (B) after adjustment for
gene score confounders. The distributions are plotted for 966
autosomal mitochondrial genes (red line), the oxidative phosphor-
ylation (OXPHOS) subset (green line), and the rest of the genes in
the genome that have at least one SNP in their region (non-
mitochondrial genes; blue line) (see Materials and Methods for
details). The correction presented in panel B is following a step-
wise multivariate linear regression analysis of the most significant
SNP p-value against the first five gene properties listed in Table 1.
The x-axis is on a log10 scale in both panels.
Found at: doi:10.1371/journal.pgen.1001058.s001 (0.25 MB PDF)
Figure S2 Distribution of T2D gene p-values for small, large and
all genes before and after correction for confounders. (A) The
distribution of the mean PBestSNP
g (best SNP association p-value per
gene g) calculated across 1,000 phenotype permutations of the
Diabetes Genetics Initiative (DGI) GWA study is shown for all
genes in genome (blue line), only large genes ($100 kilobase (kb);
red line), and only small genes (#10 kb; green line). Large genes
tended to receive on average a more significant gene score (lower
p-values) than all genes in the permuted datasets, and small genes
tended to receive on average a less significant gene score (higher p-
values) than all genes. (B–D) The distribution of gene association p-
values is shown for the actual DGI study for all gene sizes (blue
line), large genes (red line) and small genes (green line) (B) before
correcting for confounders (PBestSNP
g ), and after correcting for
confounders on PBestSNP
g , such as gene size, using either (C)
phenotype permutation analysis (PGene
g ) or (D) step-wise multivar-
iate linear regression analysis (PGene0
g ). The regression-based
correction transforms the gene p-values to a distribution that is
close to uniform and removes the confounding effect of gene size,
similar to the permutation-based correction, which corrects for all
confounding effects without a priori knowledge of them. The
regression correction seems to slightly over-correct the gene p-
values of large genes (red line in D) in the high p-value end of the
distribution (p.0.8). A bin of 0.01 was used for all four plots.
Found at: doi:10.1371/journal.pgen.1001058.s002 (0.66 MB PDF)
Figure S3 A comparison of the performance of several gene
associationscorecorrectionmethods.T2Dgeneassociationp-values
were plotted (A) before gene score adjustment (PBestSNP
g ) and after
correction forpotentialSNP-to-gene scoreconfounders (PGene0
g ), as a
function of gene p-values corrected with phenotype permutation
analysis (PGene
g ). The correction methods tested: (B) step-wise
multivariate linear regression analysis, (C) Sidak’s correction (eq. 4
in Materials and Methods) and (D) a modified version of Sidak’s
correction (eq. 5 in Materials and Methods; Saccone SF et al.,
Human Molecular Genetics 16(1): 36–49, 2007). The Diabetes
Genetics Initiative (DGI) study was used for the analysis, as we had
access to genotype data in this study. The unadjusted gene p-value,
PBestSNP
g is the association p-value of the best regional SNP for gene
g (y-axis in A). Phenotype permutation analysis was used as the gold
standard to test goodness of gene score correction as it corrects for
all confounders without requiring a priori knowledge of the
confounders (PGene
g ). The Pearson’s correlation coefficient (calcu-
lated between p-value vectors before log transformation) increased
significantly following each of the three correction methods (from
r=0.69 to r=0.94–0.97), but the Sidak’s correction (C) did not
perform as well, as it tends to overcorrect (most of the dots fall below
the diagonal, the red line). The spread around the diagonal also
decreased for all three correction methods. While the modified
Sidak’s correction (D) performs a bit better than the regression-
based correction (B) in the DGI study, Figure S4 shows that its
performance varies between GWA studies of different SNP
densities. The correction for linkage between SNPs in the modified
Sidak’s correction equation may need to be adjusted for different
GWA studies or meta-analyses with different SNP densities (see
Figure S4 for details). The minimum PGene
g is 10
24 as the p-values
were calculated based on 1,000 permutations for genes with
PGene
g w0:01 and 10,000 permutations for genes with PGene
g ƒ0:01.
Gene scores are plotted on a 2log10(p-value) scale.
Found at: doi:10.1371/journal.pgen.1001058.s003 (0.42 MB PDF)
Figure S4 Distribution of gene association p-values for different
T2D GWA studies and gene score correction methods. Presented
here are the distributions of the best SNP per gene p-values for all
genes after adjustment for confounders (PGene0
g ), using two different
correction methods: (A–B) a step-wise multivariate linear regres-
sion analysis that regresses out physical and linkage-related
confounders from the most significant SNP association z-score,
and (C–D) a modification of the Sidak’s correction equation that
uses an exponent of about half the number of SNPs per gene to
adjust for linkage disequilibrium between SNPs in a given
chromosomal region (eq. 5 in Materials and Methods). A bin of
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g
following regression analysis is similar for the DGI study (A) that
contains ,3.8e5 genotyped SNPs (on average 1 SNP/8kb) and the
DIAGRAM+ T2D meta-analysis (B) that contains ,2.3e6
genotyped or imputed SNPs (on average 1 SNP/1.3kb). The
regression-corrected PGene0
g distributions in both studies are close to
uniform, aside for an excess in the low p-value tail and a slight
deviation from uniformity in the high p-value tail. Panels A and B
show that the regression correction, which explicitly takes into
account linkage disequilibrium properties between SNPs in a gene-
specific manner, is adjustable to studies with different SNP
densities and linkage properties. The distribution of PGene0
g
following the modified Sidak’s method is also close to uniform in
the DGI study (C). However, in the DIAGRAM+ meta-analysis,
which contains about 6-fold more SNPs than the DGI study, the
modified Sidak’s correction distribution is largely skewed towards
high values of PGene0
g (D) (,11.4% of genes with PGene0
g w0:999
where only 0.1% is expected, and ,19.4% of genes with
PGene0
g w0:99 where only 1% is expected). This difference in
performance of the modified Sidak correction between the DGI
and DIAGRAM+ studies may be due to differences in SNP
density, which may affect the effective fraction of SNPs that are in
tight linkage disequilibrium in different regions along the genome.
Hence, the exponent in Sidak’s equation (eq. 5 in Materials and
Methods) might need to be adjusted for different studies.
Found at: doi:10.1371/journal.pgen.1001058.s004 (0.42 MB PDF)
Figure S5 Using simulations to find an optimal gene set
enrichment cutoff. The power of detecting gene set enrichment
of multiple modest (A) or weak (B) effects was estimated with
simulations as a function of fractions of causal genes in a gene set
of 100 genes, for five different enrichment cutoffs: 99
th percentile
(black line), 95
th percentile (dark blue line), 90
th percentile (green
line), 75
th percentile (red line), or 50
th percentile (cyan line) of all
corrected gene p-values (with regression analysis). The modest
effect size in (A) represents 1% power of detecting an association at
genome-wide significance (p-value,5e-8) using single SNP anal-
ysis, and the weak effect size in (B) represents 1% power of
detecting an association at p-value,1e-4 using single SNP analysis.
A total of 100 causal genes in the genome was assumed here.
These plots show that power of MAGENTA to detect enrichment
of multiple modest effects is fairly robust to the enrichment cutoff
used. Overall, the 95
th percentile cutoff performed the best. While
the 99
th and 95
th percentile cutoffs performed similarly in
detecting enrichment of multiple modest effects (A), the 95
th
percentile cutoff performed significantly better in detecting
enrichment of many weak effects (B). Note the log10 scale of the
x-axis in both panels.
Found at: doi:10.1371/journal.pgen.1001058.s005 (0.41 MB PDF)
Figure S6 Power of MAGENTA as a function of effect size and
total number of causal genes in the genome. (A) Power of detecting
gene set enrichment of multiple modest associations increases with
effect size. Using computer simulations we assessed the power of
MAGENTA to detect enrichment of multiple SNPs of modest
effect spiked into various fractions of genes (causal genes) in a gene
set size of 100 genes (one SNP per gene). Two different effect sizes
were tested: (i) the modest effect (solid line) represents 1% power of
detecting a SNP association at genome-wide significance (p-
value,5e-8) using single SNP analysis, and the weak effect (dashed
line) represents 1% power of detecting an association at p-
value,1e-4 using single SNP analysis (details in Materials and
Methods). A similar trend was obtained for a gene set size of 25
and 1,000 genes (data not shown). The false positive rate for the
parameters used here was between 0.4–1.7%. (B) Power of
detecting gene set enrichment of modest associations decreases as
the total number of causal genes in the genome increases. Power
was estimated assuming a total of 100 (solid line) or 500 (dashed
line) causal genes in the genome. For both panels a gene set was
considered significant at a GSEA p-value cutoff of PGSEA
gs ,0.01.
Note the logarithmic scale of the x-axis for both plots.
Found at: doi:10.1371/journal.pgen.1001058.s006 (0.28 MB PDF)
Figure S7 Quantile-quantile plots of T2D gene association p-
values for mitochondria-related gene sets. The T2D gene
association p-values adjusted for confounding effects using step-
wise multivariate linear regression analysis, PGene0
g (see Materials
and Methods) were plotted for (A) 16 nuclear regulators of
mitochondrial genes, (B) 91 oxidative phosphorylation genes, and
(C) all known nuclear-encoded autosomal mitochondrial genes
with at least one SNP in their region (955 genes), as a function of
their corresponding null distributions of PGene0
g assuming a
uniform distribution. Three mitochondrial genes that lie near
validated T2D SNPs, as of the most recent DIAGRAM+ T2D
meta-analysis are labeled in red (IDE, C8orf38,a n dACADS). The
red line marks the diagonal, and the dashed lines represent 5%
and 95% confidence intervals estimated based on 1,000 randomly
sampled gene sets from the genome of identical set size to the
given gene set. All gene p-values lie within the non-parametric
95% confidence intervals. Similar results were obtained when the
observed gene p-values were plotted against an expected
distribution that was adjusted according to a non-parametric
null distribution, generated based on 1,000 randomly sampled
gene sets from the genome of identical size to that of the tested
gene set (data not shown). PGene0
g is plotted on a 2log10(p-value)
scale. Note the x and y-axes of the three plots are not on the same
scale.
Found at: doi:10.1371/journal.pgen.1001058.s007 (0.31 MB PDF)
Figure S8 Distribution of T2D gene association p-values
following correction for confounders. (A) The distribution of the
unadjusted best SNP association p-value, PBestSNP
g for all genes g in
the genome is shown using the Diabetes Genetics Initiative (DGI)
GWA study. Since the most significant SNP in a gene region was
chosen for each gene the distribution is skewed towards low p-
values. (B) The distribution of all DGI gene p-values following
correction for confounders using phenotype permutation analysis
(PGene
g ) demonstrates how the correction transforms PBestSNP
g into a
uniform distribution. An excess of significant genes is seen at
PGene
g ,0.001. (C) The distribution of all DGI gene p-values
following correction using step-wise multivariate linear regression
analysis (PGene0
g ) on the first four confounders listed in Table 1 is
close to uniform, similar to PGene
g (in panel B). A slight deviation
from uniformity is seen for PGene0
g at the less significant end of the
p-values. An excess of significant genes is also observed at
PGene0
g ,0.001. (D) The distribution of all gene p-values computed
for the DIAGRAM+ T2D GWA meta-analysis, following step-
wise linear regression of PBestSNP
g against the first five confounders
listed in Table 1 (PGene0
g ) transforms the skewed PBestSNP
g
distribution to a reasonably uniform one, similar to the DGI
study. An excess of significant genes is also observed at
PGene0
g ,0.001. A bin of 0.001 was used for all four plots.
Found at: doi:10.1371/journal.pgen.1001058.s008 (0.53 MB PDF)
Figure S9 Power of MAGENTA as a function of gene set
enrichment significance threshold. We compared the effect of two
p-value thresholds used to call a gene set significantly enriched in a
given simulation run, on the power of MAGENTA to detect gene
set enrichment. The two cutoffs tested were: PGSEA
gs ,0.01 (solid
line) and PGSEA
gs ,0.001 (dashed line). PGSEA
gs is the nominal
enrichment p-value for gene set gs. Power is plotted as a function of
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with a modest effect size equivalent to 1% power of detecting an
association at genome-wide significance (p-value,5e-8) using
single SNP analysis. Two gene set sizes were examined: 100
genes (squares) and 1,000 genes (circles). Power appears to
decrease only slightly with a more stringent GSEA p-value
threshold. Note the x-axis is on a log10 scale.
Found at: doi:10.1371/journal.pgen.1001058.s009 (0.24 MB PDF)
Table S1 Average gene size of nuclear-encoded mitochondrial
genes compared to non-mitochondrial genes. Mitochondrial
genes refer to nuclear-encoded mitochondrial genes on autosomal
chromosomes taken from the MitoCarta compendium (Pagliarini
DJ, et al. (2008), Cell 134: 112–123). OXPHOS genes refer to the
oxidative phosphorylation gene subset. The calculations are based
on the March 2006 (hg18) assembly of all human genes. bp, base
pairs.
Found at: doi:10.1371/journal.pgen.1001058.s010 (0.04 MB PDF)
Table S2 Correlation between T2D gene association scores,
computed from DIAGRAM+ meta-analysis, and six potential
confounders. Pearson’s correlation coefficient (r) was calculated
between the unadjusted and adjusted best SNP per gene z-scores,
ZBestSNP and ZGene0
, respectively, and six physical and linkage-
related gene properties, using the DIAGRAM+ T2D GWA study
meta-analysis. Aside for gene size, all gene properties were divided
by the size of the gene plus its extended physical boundaries
(150 kb was added to the most extreme transcript size for each
gene, as the 2110kb/+40kb extended gene boundary was used).
ZBestSNP is a vector of the uncorrected gene z-scores for all genes
in genome, and ZGene0
is a vector of corrected gene z-scores for all
genes, using step-wise multivariate linear regression analysis. All
correlations between ZBestSNP and the six variables were
statistically significant (p,1e-28).
{These gene properties were
significant at p,0.05 under a step-wise multivariate linear
regression model that regresses ZBestSNP against all six gene
properties (see Table S4 for regression model parameters and p-
values).
Found at: doi:10.1371/journal.pgen.1001058.s011 (0.20 MB PDF)
Table S3 Using GWA permutations to identify significant
confounders on gene scores under a multivariate regression
model. For each of the 1,000 Diabetes Genetic Initiative (DGI)
GWA study permutations (described in Materials and Methods)
we applied step-wise multivariate linear regression analysis to the
most significant SNP per gene p-value, PBestSNP
g for all genes g,
against the six gene properties listed in the table. We used the
fraction of permuted GWA studies for which a given gene
property was included in the regression model (at p,0.05) to assess
the significance of each gene property as a confounder on
PBestSNP
g . GWA study permutations are not expected to contain
true associations, and hence any correlation between PBestSNP
g and
a gene property in a permuted dataset should be due solely to
artificial or confounding effects. All gene properties aside for gene
size were divided by the size of the gene and its extended physical
boundaries (the gene boundaries used in this analysis were 650kb
around the gene’s most extreme transcript boundaries). For all
gene set analyses performed in this paper, we chose to include the
gene properties that were significant under the regression model in
at least ,50% of permutations for gene score adjustment, and
therefore we used the first five properties listed in this table. We
obtained very similar GSEA results for all gene sets and GWA
studies tested in this paper, when only the first four properties
listed in the table, that were significant in almost all permutations
tested, were used (data not shown).
Found at: doi:10.1371/journal.pgen.1001058.s012 (0.13 MB PDF)
Table S4 Parameters of step-wise multivariate linear regression
models of T2D gene scores against gene score confounders. The
parameters of a step-wise multivariate linear regression model of
the best SNP p-value, PBestSNP
g (the response variable) for all genes
g, on five gene properties (potential gene score confounders; the
predictor variables) are listed here for the Diabetes Genetics
Initiative (DGI) GWA study and the DIAGRAM+ T2D GWA
meta-analysis. The confounding variables imputed into the
regression model were those variables that were significant under
the regression model in more than about half of the 1,000 DGI
GWA permutations tested (Table S3). Hence, only the first five out
of six properties listed in Table 1 were considered here. At each
step of the regression analysis, an additional variable (gene score
confounder) is added for consideration under the regression
model. Variables with p,0.05 were considered significant and
included in the regression model, and variables with p.0.1 were
removed from the model. Variables are listed in the table in
the order they were added to the model. Similar ß coefficients
and p-values were obtained within each study using either
2110kb/+40kb gene boundaries or 650kb boundaries. The main
differences between the DGI GWA study and the DIAGRAM+
meta-analysis were in the ß coefficients of SNP density and of
linkage disequilibrium unit density. The ß coefficient for SNP
density is smaller in the DIAGRAM+ meta-analysis compared to
the DGI study, possibly because the overall SNP density is much
larger in the meta-analysis (,6-fold higher), which may decrease
the difference in SNP density between small and large genes. The
linkage disequilibrium unit gene property was not considered
significant for the DGI study. This may also be due to differences
in SNP density, since a lower SNP density may decrease the
fraction of SNPs in a given chromosomal region that are in strong
linkage disequilibrium.
{All gene properties aside for gene size
were divided by the size of the gene and its extended physical
boundaries. *p-value is the probability for testing the null
hypothesis that ß=0 (i.e. probability that a variable should not
be added to the regression model).
Found at: doi:10.1371/journal.pgen.1001058.s013 (0.13 MB PDF)
Table S5 GSEA results for lipid and lipoprotein-related
pathways using LDL cholesterol GWA meta-analysis of 19,840
individuals. A total of 51 (partially overlapping) gene sets related to
lipid, lipoprotein and fatty acid metabolism taken from the
PANTHER and Gene Ontology databases were tested with
MAGENTA for enrichment of genetic associations to LDL
cholesterol blood levels, using a GWA meta-analysis of 19,840
individuals (Kathiresan S. et al., 2009, Nature Genetics 41: 56–65).
GSEA p-values that passed the Bonferroni significance threshold
were marked with an asterisk (each database was corrected for
multiple hypothesis testing separately due to considerable overlap
between the gene sets from the different databases). The
Bonferroni cutoffs for the different databases are: PANTHER
(15 pathways): p,0.0033, Gene Ontology, biological process terms
(29 gene sets): p,0.0017, and Gene Ontology, molecular function
terms (7 gene sets): p,0.0071. In the third column, GSEA p-values
in parentheses are following exclusion of 19 genes that lie near 11
validated SNPs associated with LDL cholesterol (taken from
Table 2 in Kathiresan S. et al., 2009). Interestingly, the association
signals of some of the gene sets, including lipid and lipoprotein
metabolism and lipid transport processes are still detectable when
genes near validated SNPs are removed from the GSEA analysis.
The 95
th percentile of the adjusted LDL gene association p-values
(PGene0
g ) for all genes in the genome was used as the gene set
enrichment cutoff.
Found at: doi:10.1371/journal.pgen.1001058.s014 (0.05 MB PDF)
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pathways using HDL cholesterol GWA meta-analysis of 19,840
individuals. A total of 51 (partially overlapping) gene sets related to
lipid, lipoprotein and fatty acid metabolism taken from the
PANTHER and Gene Ontology databases were tested with
MAGENTA for enrichment of genetic associations to HDL
cholesterol blood levels, using a GWA meta-analysis of 19,840
individuals (Kathiresan S. et al., 2009, Nature Genetics 41: 56–65).
GSEA p-values that passed the Bonferroni significance threshold
were marked with an asterisk (each database was corrected for
multiple hypothesis testing separately due to considerable overlap
between the gene sets from the different databases). The
Bonferroni cutoffs for the different databases are: PANTHER
(15 pathways): p,0.0033, Gene Ontology, biological process terms
(29 gene sets): p,0.0017, and Gene Ontology, molecular function
terms (7 gene sets): p,0.0071. In the third column, GSEA p-values
in parentheses are following exclusion of 20 genes that lie near 14
validated SNPs associated with HDL cholesterol (taken from
Table 2 in Kathiresan S. et al., 2009). Interestingly, the association
signals of some of the gene sets, including lipid metabolism,
binding and transport processes and triacylglycerol metabolism are
still detectable when genes near validated HDL cholesterol SNPs
are removed from the GSEA analysis. The 95
th percentile of the
adjusted HDL gene association p-values (PGene0
g ) for all genes in the
genome was used as the gene set enrichment cutoff.
Found at: doi:10.1371/journal.pgen.1001058.s015 (0.05 MB PDF)
Table S7 GSEA results for lipid and lipoprotein-related
pathways using triglyceride GWA meta-analysis of 19,840
individuals. A total of 51 (partially overlapping) gene sets related
to lipid, lipoprotein and fatty acid metabolism taken from the
PANTHER and Gene Ontology databases were tested with
MAGENTA for enrichment of genetic associations to triglyceride
blood levels, using a GWA meta-analysis of 19,840 individuals
(Kathiresan S. et al., 2009, Nature Genetics 41: 56–65). GSEA p-
values that passed the Bonferroni significance threshold were
marked with an asterisk (each database was corrected for multiple
hypothesis testing separately due to considerable overlap between
the gene sets from the different databases). The Bonferroni cutoffs
for the different databases are: PANTHER (15 pathways):
p,0.0033, Gene Ontology, biological process terms (29 gene
sets): p,0.0017, and Gene Ontology, molecular function terms (7
gene sets): p,0.0071. In the third column, GSEA p-values in
parentheses are following exclusion from the analysis of 19 genes
that lie near 11 validated SNPs associated with triglyceride levels
(taken from Table 2 in Kathiresan S. et al., 2009). Interestingly, the
association signals of some of the gene sets, in particular
phospholipid binding and metabolic processes are still detectable
when genes near validated SNPs are removed from the GSEA
analysis. The 95
th percentile of the adjusted triglyceride gene
association p-values (PGene0
g ) for all genes in the genome was used
as the gene set enrichment cutoff.
Found at: doi:10.1371/journal.pgen.1001058.s016 (0.05 MB
PDF)
Table S8 GSEA of LDL cholesterol GWA meta-analysis is
robust to the gene score correction method used. GSEA results for
lipid and lipoprotein-related gene sets using a GWA meta-analysis
of LDL cholesterol blood levels (Kathiresan S. et al., 2009, Nature
Genetics 41: 56–65) are presented following two different gene
score correction methods: a modified version of Sidak’s correction,
proposed by Saconne et al. (Saccone SF et al., Human Molecular
Genetics 16(1): 36–49, 2007) (column 3) and a step-wise
multivariate regression analysis method (column 4). GSEA p-
values that passed the Bonferroni significance threshold are
marked with an asterisk (each database was corrected for multiple
hypothesis testing separately, due to considerable overlap between
the gene sets from the different databases). The GSEA results are
quite robust to the correction method used. In the third and fourth
columns, GSEA p-values in parentheses are following exclusion of
19 genes that lie near 11 validated SNPs associated with LDL
cholesterol (taken from Table 2 in Kathiresan S. et al., 2009). The
number of genes analyzed by MAGENTA in column 2 was taken
from the analysis that applied the modified Sidak’s correction of
gene p-values. This number was in most cases identical to that
following regression-based correction (Table S5). The 95
th
percentile of the adjusted LDL cholesterol gene association p-
values (PGene0
g ) for all genes in the genome was used as the gene set
enrichment cutoff.
Found at: doi:10.1371/journal.pgen.1001058.s017 (0.06 MB PDF)
Table S9 GSEA of HDL cholesterol GWA meta-analysis is
robust to the gene score correction method used. GSEA results
for lipid and lipoprotein-related gene sets using a GWA meta-
analysis of HDL cholesterol blood levels (Kathiresan S. et al.,
2009, Nature Genetics 41: 56–65) are presented following two
different gene score correction methods: a modified version of
Sidak’s correction, proposed by Saconne et al. (Saccone SF et al.,
Human Molecular Genetics 16(1): 36–49, 2007) (column 3) and a
step-wise multivariate regression analysis method (column 4).
GSEA p-values that passed the Bonferroni significance threshold
are marked with an asterisk (each database was corrected for
multiple hypothesis testing separately, due to considerable
overlap between the gene sets from the different databases).
The GSEA results are quite robust to the correction method
used. GSEA p-values in parentheses are following exclusion from
the analysis of 20 genes that lie near 14 validated SNPs associated
with HDL cholesterol (taken from Table 2 in Kathiresan S. et al.,
2009). The number of genes analyzed by MAGENTA in column
2 was taken from the analysis that used the modified Sidak’s
correction of gene p-values. This number was in most cases
identical to that following regression-based correction (Table S5).
The 95
th percentile of the adjusted HDL cholesterol gene
association p-values (PGene0
g ) for all genes in the genome was used
as the gene set enrichment cutoff.
Found at: doi:10.1371/journal.pgen.1001058.s018 (0.05 MB PDF)
Table S10 GSEA of triglyceride GWA meta-analysis is robust to
the gene score correction method used. GSEA results for lipid and
lipoprotein-related gene sets using a GWA meta-analysis of
triglyceride blood levels (Kathiresan S. et al.,2 0 0 9 ,N a t u r eG e n e t i c s
41: 56–65) are presented following two different gene score correction
methods: a modified version of Sidak’s correction, proposed by
Saconne et al. (Saccone SF et al., Human Molecular Genetics 16(1):
36–49, 2007) (column 3) and a step-wise multivariate regression
analysis method (column 4). GSEA p-values that passed the
Bonferroni significance threshold are marked with an asterisk (each
database was corrected for multiple hypothesis testing separately, due
to considerable overlap between the gene sets from the different
databases). The GSEA results are quite robust to the correction
method used. GSEA p-values in parentheses are following exclusion
from the analysis of 19 genes that lie near 11 validated SNPs
associated with triglyceride blood levels (list of known genes taken
from Table 2 in Kathiresan S. et al., 2009). The number of genes
analyzed by MAGENTA in column 2 was taken from the analysis
that used the modified Sidak’s correction method. This number was
in most cases identical to that following regression-based correction
(Table S5). The 95
th percentile of the adjusted triglyceride gene
association p-values (PGene0
g ) for all genes in the genome was used as
the gene set enrichment cutoff.
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Table S11 List of nuclear regulators of mitochondrial genes and
their T2D association scores. T2D gene p-values adjusted for
confounding effects with step-wise multivariate linear regression
analysis (PGene0
g ) were computed for 16 known nuclear regulators of
nuclear-encoded mitochondrial genes, using the DIAGRAM+
T2D GWA study meta-analysis (Voight BF et al., Nature Genetics,
in press, 2010).
Found at: doi:10.1371/journal.pgen.1001058.s020 (0.02 MB
XLS)
Table S12 List of T2D gene association scores for all known
autosomal mitochondrial genes taken from MitoCarta. T2Dgene p-
values adjusted for confounders with multivariate linear regression
analysis (PGene0
g ) are listed for 966 nuclear-encoded (autosomal)
mitochondrial genes, taken from the MitoCarta compendium
(Pagliarini DJ, et al., 2008, Cell 134: 112–123). The DIAGRAM+
T2D GWA study meta-analysis (Voight BF, et al., Nature Genetics,
in press, 2010) was used here. Genes in bold lie near validated T2D
SNPs, as of the DIAGRAM+ meta-analysis. The last column marks
genes that belong to the oxidative phosphorylation (OXPHOS)
pathwaywiththenumber 1.‘NaN’referstogenesthathadnoSNPs
in their extended gene boundaries (110kb upstream to the gene’s
most extreme transcript start site, and 40kb downstream to the
gene’s transcript most extreme end site).
Found at: doi:10.1371/journal.pgen.1001058.s021 (0.23 MB
XLS)
Table S13 GSEA results of mitochondria-related gene sets are
robust to GSEA statistical test used. We tested the robustness of the
mitochondria-related gene set enrichment results with respect to
T2D and seven diabetes-relevant glycemic traits by using an
alternative GSEA statistical test to the enrichment cutoff approach.
A one-tailedMann-Whitneyrank-sum test was applied(described in
Materials and Methods) to GWA study meta-analyses of T2D and
seven glucose and insulin-related traits. PGSEA
gs is the nominal gene
set enrichment p-value for gene set gs computed for each phenotype
separately. The enrichment cutoff used was the 95
th percentile of all
gene p-values computed from the corresponding GWA meta-
analysis. The GSEA results obtained with the rank-sum approach
are very similar to those obtained using the enrichment cutoff
approach (see Table 3 and Table 4). HOMA-IR is an index for
insulin resistance, HOMA-B is an index for b-cell function, and
HbA1C represents glycated hemoglobin concentrations. OXPHOS
stands for the oxidative phosphorylation process. The nuclear
regulators are regulators of nuclear-encoded mitochondrial genes.
{These gene sets are not significant after Bonferroni correction
(most stringent cutoff p,0.002, given 3 gene sets and 8 traits tested;
a less stringent cutoff p,0.0083, correcting for 3 gene sets and 2
traits due to considerable correlation between the glucose and
insulin-related traits).
Found at: doi:10.1371/journal.pgen.1001058.s022 (0.15 MB PDF)
Table S14 GSEA results of mitochondria-related gene sets are
robust to the gene score correction method used. We tested the
effect of using a different gene score correction method other than
the regression-based method on mitochondria-related gene set
enrichment results with respect to type 2 diabetes and seven related
glycemic traits. We applied a modification of the Sidak’s correction
(described in Materials and Methods; Saccone SF et al., Human
Molecular Genetics 16(1): 36–49, 2007) to correct for confounding
effectson the most significant SNP p-value, PBestSNP
g for eachgene g.
PGSEA
gs is the nominal gene set enrichment (GSEA) p-value for gene
set gs computed for each phenotype separately. The enrichment
cutoff used was the 95
th percentile of all gene scores computed from
the corresponding GWA study meta-analysis. HOMA-IR is an
index for insulin resistance, HOMA-B is an index for b-cell
function, and HbA1C represents glycated hemoglobin concentra-
tions. OXPHOS stands for the oxidative phosphorylation process.
The nuclear regulators are regulators of nuclear-encoded mito-
chondrial genes.
{ This gene set is not significant after Bonferroni
correction (most stringent cutoff p,0.002, given 3 gene sets and 8
traits tested; a less stringent cutoff p,0.0083, correcting for 3 gene
sets and 2 traits due to considerable correlation between the glucose
and insulin-related traits and type 2 diabetes). The GSEA results are
comparable to those using step-wise multivariate linear regression
analysis to correct for confounders on gene association p-values
(Table 3 and Table 4).
Found at: doi:10.1371/journal.pgen.1001058.s023 (0.16 MB PDF)
Text S1 Lists of consortia participants and affiliations.
Found at: doi:10.1371/journal.pgen.1001058.s024 (0.10 MB
DOC)
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